Clifford Jack

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1397145/publications.pdf

Version: 2024-02-01

959 papers	127,182 citations	216 152 h-index	218 317 g-index
1004 all docs	1004 docs citations	1004 times ranked	67323 citing authors

#	Article	IF	Citations
1	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 263-269.	0.4	12,681
2	NIAâ€AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 535-562.	0.4	5,861
3	Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 280-292.	0.4	5,550
4	Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine, 2004, 256, 240-246.	2.7	4,039
5	Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurology, The, 2010, 9, 119-128.	4.9	3,792
6	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurology, The, 2013, 12, 207-216.	4.9	3,378
7	The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. Journal of Magnetic Resonance Imaging, 2008, 27, 685-691.	1.9	2,553
8	Introduction to the recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 257-262.	0.4	1,547
9	The clinical use of structural MRI in Alzheimer disease. Nature Reviews Neurology, 2010, 6, 67-77.	4.9	1,505
10	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology, 2016, 87, 539-547.	1.5	1,216
11	Mild Cognitive Impairment. Archives of Neurology, 2009, 66, 1447-55.	4.9	1,160
12	Automatic classification of MR scans in Alzheimer's disease. Brain, 2008, 131, 681-689.	3.7	1,017
13	Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology, 1997, 49, 786-794.	1.5	994
14	Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain, 2009, 132, 1355-1365.	3.7	975
15	Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). , 2005, 1, 55-66.		925
16	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain, 2019, 142, 1503-1527.	3.7	873
17	The Alzheimer's Disease Neuroimaging Initiative. Neuroimaging Clinics of North America, 2005, 15, 869-877.	0.5	863
18	Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials. Archives of Neurology, 2004, 61, 59.	4.9	853

#	Article	IF	Citations
19	11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain, 2008, 131, 665-680.	3.7	819
20	MRâ€based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology, 1992, 42, 183-183.	1.5	809
21	Biomarker Modeling of Alzheimerâ€™s Disease. Neuron, 2013, 80, 1347-1358.	3.8	773
22	Common genetic variants influence human subcortical brain structures. Nature, 2015, 520, 224-229.	13.7	772
23	Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology, 2004, 62, 591-600.	1.5	726
24	The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging and Behavior, 2014, 8, 153-182.	1.1	696
25	Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease. JAMA - Journal of the American Medical Association, 2010, 304, 1903.	3.8	626
26	Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain, 2006, 129, 1385-1398.	3.7	624
27	Identification of common variants associated with human hippocampal and intracranial volumes. Nature Genetics, 2012, 44, 552-561.	9.4	594
28	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 205-216.	0.4	581
29	3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain, 2007, 130, 1777-1786.	3.7	541
30	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's and Dementia, 2013, 9, e111-94.	0.4	535
31	Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimerâ€™s Association Research Roundtable Workgroup. , 2011, 7, 367-385.		531
32	An operational approach to National Institute on Agingâ€"Alzheimer's Association criteria for preclinical Alzheimer disease. Annals of Neurology, 2012, 71, 765-775.	2.8	520
33	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, The, 2017, 16, 661-676.	4.9	464
34	Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology, 2005, 65, 1227-1231.	1.5	462
35	Testing the Right Target and Right Drug at the Right Stage. Science Translational Medicine, 2011, 3, 111cm33.	5.8	459
36	Magnetic resonance imaging-based volume studies in temporal lobe epilepsy: Pathological correlations. Annals of Neurology, 1991, 30, 31-36.	2.8	458

#	Article	IF	Citations
37	Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain, 2010, 133, 3336-3348.	3.7	455
38	The genetic architecture of the human cerebral cortex. Science, 2020, 367, .	6.0	450
39	The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans. Alzheimer's and Dementia, 2010, 6, 202.	0.4	443
40	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's and Dementia, 2012, 8, S1-68.	0.4	432
41	Magnetic resonance image-based hippocampal volumentry: Correlation with outcome after temporal lobectomy. Annals of Neurology, 1992, 31, 138-146.	2.8	430
42	Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans. Alzheimer's and Dementia, 2010, 6, 239-246.	0.4	402
43	Cascading network failure across the Alzheimerâ€™s disease spectrum. Brain, 2016, 139, 547-562.	3.7	401
44	Alzheimer's disease diagnosis in individual subjects using structural MR images: Validation studies. NeuroImage, 2008, 39, 1186-1197.	2.1	391
45	An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathologica Communications, 2016, 4, 58.	2.4	388
46	Plasma phosphoâ€tau181 increases with Alzheimer's disease clinical severity and is associated with tauâ€• and amyloidâ€positron emission tomography. Alzheimer's and Dementia, 2018, 14, 989-997.	0.4	386
47	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurology, The, 2018, 17, 241-250.	4.9	383
48	Non-Stationarity in the â€œResting Brainâ€™sâ€•Modular Architecture. PLoS ONE, 2012, 7, e39731.	1.1	382
49	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. Annals of Neurology, 2016, 79, 929-939.	2.8	381
50	Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimer's and Dementia, 2010, 6, 265-273.	0.4	378
51	Magnetic resonance elastography of the brain. NeuroImage, 2008, 39, 231-237.	2.1	375
52	Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain, 2012, 135, 794-806.	3.7	355
53	Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurology, The, 2012, 11, 868-877.	4.9	355
54	Patterns of atrophy in pathologically confirmed FTLD with and without motor neuron degeneration. Neurology, 2006, 66, 102-104.	1.5	351

#	Article	IF	Citations
55	Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiology of Aging, 2012, 33, 1203-1214.e2.	1.5	346
56	Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. NeuroImage, 2010, 53, 1051-1063.	2.1	340
57	TDP-43 is a key player in the clinical features associated with Alzheimerâ€™s disease. Acta Neuropathologica, 2014, 127, 811-824.	3.9	336
58	Brain Î²-amyloid load approaches a plateau. Neurology, 2013, 80, 890-896.	1.5	335
59	Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech. Brain, 2012, 135, 1522-1536.	3.7	325
60	Drug development in Alzheimerâ€™s disease: the path to 2025. Alzheimer's Research and Therapy, 2016, 8, 39.	3.0	323
61	Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain, 2012, 135, 765-783.	3.7	322
62	Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: An MRI study of 676 AD, MCI, and normal subjects. NeuroImage, 2008, 43, 458-469.	2.1	317
63	On the path to 2025: understanding the Alzheimerâ€™s disease continuum. Alzheimer's Research and Therapy, 2017, 9, 60.	3.0	316
64	Age-related changes in the default mode network are more advanced in Alzheimer disease. Neurology, 2011, 77, 1524-1531.	1.5	313
65	Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2010, 6, 212-220.	0.4	311
66	Regional variability of imaging biomarkers in autosomal dominant Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4502-9.	3.3	309
67	Longitudinal tau PET in ageing and Alzheimerâ€™s disease. Brain, 2018, 141, 1517-1528.	3.7	309
68	Age, Sex, andAPOEÎµ4 Effects on Memory, Brain Structure, and Î²-Amyloid Across the Adult Life Span. JAMA Neurology, 2015, 72, 511.	4.5	305
69	Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2019, 15, 106-152.	0.4	302
70	Age-specific population frequencies of cerebral Î²-amyloidosis and neurodegeneration among people with normal cognitive function aged 50â€“89 years: a cross-sectional study. Lancet Neurology, The, 2014, 13, 997-1005.	4.9	297
71	Mild Cognitive Impairment and Alzheimer Disease: Regional Diffusivity of Water. Radiology, 2001, 219, 101-107.	3.6	293
72	Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain, 2007, 130, 708-719.	3.7	286

#	Article	IF	Citations
73	Modifiable factors that alter the size of the hippocampus with ageing. Nature Reviews Neurology, 2012, 8, 189-202.	4.9	282
74	MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology, 2003, 60, 253-260.	1.5	279
75	Staging TDP-43 pathology in Alzheimerâ€™s disease. Acta Neuropathologica, 2014, 127, 441-450.	3.9	278
76	Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain, 2009, 132, 2932-2946.	3.7	277
77	Decreased brain stiffness in Alzheimer's disease determined by magnetic resonance elastography. Journal of Magnetic Resonance Imaging, 2011, 34, 494-498.	1.9	277
78	Effectiveness of regional DTI measures in distinguishing Alzheimer's disease, MCI, and normal aging. NeuroImage: Clinical, 2013, 3, 180-195.	1.4	277
79	Clinicopathologic and¹¹C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimerâ€™s disease spectrum. Brain, 2015, 138, 1370-1381.	3.7	270
80	The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimer's and Dementia, 2017, 13, 561-571.	0.4	266
81	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: AÂreview of papers published since its inception. Alzheimer's and Dementia, 2015, 11, e1-120.	0.4	261
82	Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimer's and Dementia, 2010, 6, 230-238.	0.4	256
83	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	4.9	254
84	Novel genetic loci associated with hippocampal volume. Nature Communications, 2017, 8, 13624.	5.8	250
85	A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. NeuroImage: Clinical, 2016, 11, 802-812.	1.4	249
86	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurology, The, 2014, 13, 676-685.	4.9	245
87	Age-specific and sex-specific prevalence of cerebral Î²-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50â€“95 years: a cross-sectional study. Lancet Neurology, The, 2017, 16, 435-444.	4.9	241
88	Diagnostic neuroimaging across diseases. NeuroImage, 2012, 61, 457-463.	2.1	240
89	Predicting clinical scores from magnetic resonance scans in Alzheimer's disease. NeuroImage, 2010, 51, 1405-1413.	2.1	235
90	Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurology, 2016, 73, 721.	4.5	235

#	Article	IF	Citations
91	Longitudinal MRI atrophy biomarkers: Relationship to conversion in the ADNI cohort. Neurobiology of Aging, 2010, 31, 1401-1418.	1.5	230
92	Suspected non-Alzheimer disease pathophysiology â€" concept and controversy. Nature Reviews Neurology, 2016, 12, 117-124.	4.9	230
93	A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8404-8409.	3.3	227
94	Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology, 2012, 78, 1576-1582.	1.5	227
95	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 2316.	3.8	223
96	Accuracy of dementia diagnosis--a direct comparison between radiologists and a computerized method. Brain, 2008, 131, 2969-2974.	3.7	222
97	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain, 2015, 138, 761-771.	3.7	222
98	Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiology of Aging, 2008, 29, 280-289.	1.5	221
99	Sex, Apolipoprotein E Îµ4 Status, and Hippocampal Volume in Mild Cognitive Impairment. Archives of Neurology, 2005, 62, 953.	4.9	218
100	Widespread brain tau and its association with ageing, Braak stage and Alzheimerâ€™s dementia. Brain, 2018, 141, 271-287.	3.7	218
101	Longitudinal Changes in White Matter Disease and Cognition in the First Year of the Alzheimer Disease Neuroimaging Initiative. Archives of Neurology, 2010, 67, 1370.	4.9	216
102	Mild cognitive impairment due to Alzheimer disease in the community. Annals of Neurology, 2013, 74, 199-208.	2.8	215
103	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
104	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	7.1	213
105	Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. Alzheimer's and Dementia, 2017, 13, e1-e85.	0.4	213
106	Common variants at 12q14 and 12q24 are associated with hippocampal volume. Nature Genetics, 2012, 44, 545-551.	9.4	212
107	Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. NeuroImage, 2009, 45, S3-S15.	2.1	211
108	Blood Pressure and White-Matter Disease Progression in a Biethnic Cohort. Stroke, 2010, 41, 3-8.	1.0	209

#	Article	IF	Citations
109	Molecular Targeting of Alzheimer's Amyloid Plaques for Contrast-Enhanced Magnetic Resonance Imaging. Neurobiology of Disease, 2002, 11, 315-329.	2.1	206
110	Imaging markers for Alzheimer disease. Neurology, 2013, 81, 487-500.	1.5	204
111	Interpreting scan data acquired from multiple scanners: A study with Alzheimer's disease. NeuroImage, 2008, 39, 1180-1185.	2.1	200
112	Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. NeuroImage, 2006, 31, 627-640.	2.1	198
113	Effect ofAPOEÎµ4 Status on Intrinsic Network Connectivity in Cognitively Normal Elderly Subjects. Archives of Neurology, 2011, 68, 1131.	4.9	197
114	Mild cognitive impairment associated with limbic and neocortical lewy body disease: a clinicopathological study. Brain, 2010, 133, 540-556.	3.7	195
115	Evidence for Ordering of Alzheimer Disease Biomarkers. Archives of Neurology, 2011, 68, 1526.	4.9	195
116	Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clinics of North America, 2003, 13, 197-209.	0.5	193
117	Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11906-11910.	3.3	193
118	Alzheimer Disease: New Concepts on Its Neurobiology and the Clinical Role Imaging Will Play. Radiology, 2012, 263, 344-361.	3.6	192
119	Genetic architecture of subcortical brain structures in 38,851 individuals. Nature Genetics, 2019, 51, 1624-1636.	9.4	192
120	MRIâ€Based Hippocampal Volume Measurements in Epilepsy. Epilepsia, 1994, 35, S21-9.	2.6	191
121	Î²â€amyloid burden is not associated with rates of brain atrophy. Annals of Neurology, 2008, 63, 204-212.	2.8	187
122	Patterns of Atrophy Differ Among Specific Subtypes of Mild Cognitive Impairment. Archives of Neurology, 2007, 64, 1130.	4.9	185
123	Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2007, 28, 1330-1339.	1.5	185
124	Comparison of ¹⁸F-FDG and PiB PET in Cognitive Impairment. Journal of Nuclear Medicine, 2009, 50, 878-886.	2.8	183
125	Chronic Divalproex Sodium to Attenuate Agitation and Clinical Progression of Alzheimer Disease. Archives of General Psychiatry, 2011, 68, 853.	13.8	183
126	Measuring the effects of aging and sex on regional brain stiffness with MR elastography in healthy older adults. NeuroImage, 2015, 111, 59-64.	2.1	183

#	Article	IF	Citations
127	Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology, 2013, 81, 1732-1740.	1.5	182
128	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Agingâ€"Alzheimerâ€™s Association Research Framework. JAMA Neurology, 2019, 76, 1174.	4.5	182
129	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimerâ€™s disease. Nature Medicine, 2021, 27, 1187-1196.	15.2	182
130	In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magnetic Resonance in Medicine, 2004, 52, 1263-1271.	1.9	181
131	Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls. NeuroImage, 2008, 43, 59-68.	2.1	181
132	Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. Neurobiology of Aging, 2010, 31, 1463-1480.	1.5	181
133	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimer's and Dementia, 2015, 11, 865-884.	0.4	181
134	Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology, 2014, 82, 1132-1141.	1.5	180
135	Spherical navigator echoes for full 3D rigid body motion measurement in MRI. Magnetic Resonance in Medicine, 2002, 47, 32-41.	1.9	179
136	Qualitative Estimates of Medial Temporal Atrophy as a Predictor of Progression From Mild Cognitive Impairment to Dementia. Archives of Neurology, 2007, 64, 108.	4.9	178
137	Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Human Brain Mapping, 2009, 30, 2766-2788.	1.9	178
138	Imaging correlates of posterior cortical atrophy. Neurobiology of Aging, 2007, 28, 1051-1061.	1.5	176
139	Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 474.	0.4	176
140	Impaired default network functional connectivity in autosomal dominant Alzheimer disease. Neurology, 2013, 81, 736-744.	1.5	174
141	Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Annals of Neurology, 1998, 43, 303-310.	2.8	173
142	Alzheimerâ€™s Disease Neuroimaging Initiative. , 2008, , 183-189.		173
143	Standardization of analysis sets for reporting results from ADNI MRI data. Alzheimer's and Dementia, 2013, 9, 332-337.	0.4	172
144	Obesity is linked with lower brain volume in 700 AD and MCI patients. Neurobiology of Aging, 2010, 31, 1326-1339.	1.5	170

#	Article	IF	Citations
145	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain, 2015, 138, 3747-3759.	3.7	170
146	Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. NeuroImage, 2005, 26, 600-608.	2.1	169
147	Dynamic MR digital subtraction angiography using contrast enhancement, fast data acquisition, and complex subtraction. Magnetic Resonance in Medicine, 1996, 36, 551-556.	1.9	167
148	Prominent phenotypic variability associated with mutations in Progranulin. Neurobiology of Aging, 2009, 30, 739-751.	1.5	166
149	Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiology of Aging, 2010, 31, 1429-1442.	1.5	165
150	Routine EEG and Temporal Lobe Epilepsy: Relation to Long-Term EEG Monitoring, Quantitative MRI, and Operative Outcome. Epilepsia, 1996, 37, 651-656.	2.6	164
151	Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology, 2008, 70, 1740-1752.	1.5	163
152	Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiology of Aging, 2012, 33, 2091-2105.	1.5	162
153	Breakdown of Brain Connectivity Between Normal Aging and Alzheimer's Disease: A Structuralk-Core Network Analysis. Brain Connectivity, 2013, 3, 407-422.	0.8	162
154	The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. Alzheimer's and Dementia, 2015, 11, 111-125.	0.4	162
155	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. Cortex, 2017, 97, 143-159.	1.1	162
156	Ecology of the Aging Human Brain. Archives of Neurology, 2011, 68, 1049.	4.9	161
157	Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Annals of Neurology, 2010, 67, 308-316.	2.8	160
158	Association of Lifetime Intellectual Enrichment With Cognitive Decline in the Older Population. JAMA Neurology, 2014, 71, 1017.	4.5	160
159	Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. JAMA Neurology, 2016, 73, 85.	4.5	160
160	Plasma and CSF neurofilament light. Neurology, 2019, 93, e252-e260.	1.5	160
161	Alzheimer's Disease Neuroimaging Initiative: A one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. NeuroImage, 2009, 45, 645-655.	2.1	159
162	Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. Lancet Neurology, The, 2017, 16, 917-924.	4.9	159

#	Article	IF	Citations
163	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. Neurobiology of Aging, 2017, 56, 172-179.	1.5	158
164	MRI-based hippocampal volumetrics: Data acquisition, normal ranges, and optimal protocol. Magnetic Resonance Imaging, 1995, 13, 1057-1064.	1.0	157
165	APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimer's and Dementia, 2015, 11, 1417-1429.	0.4	157
166	Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimer's Research and Therapy, 2014, 6, 1.	3.0	156
167	Measurement of Cerebrospinal Fluid Flow at the Cerebral Aqueduct by Use of Phase-contrast Magnetic Resonance Imaging: Technique Validation and Utility in Diagnosing Idiopathic Normal Pressure Hydrocephalus. Neurosurgery, 2002, 50, 534-543.	0.6	155
168	Brain injury biomarkers are not dependent on Î²â€amyloid in normal elderly. Annals of Neurology, 2013, 73, 472-480.	2.8	155
169	Improved DTI registration allows voxel-based analysis that outperforms Tract-Based Spatial Statistics. NeuroImage, 2014, 94, 65-78.	2.1	155
170	Multisite study of the relationships between antemortem [¹¹C]PIBâ€PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2019, 15, 205-216.	0.4	155
171	FLAIR histogram segmentation for measurement of leukoaraiosis volume. Journal of Magnetic Resonance Imaging, 2001, 14, 668-676.	1.9	152
172	Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. NeuroImage, 2008, 42, 559-567.	2.1	152
173	Regional brain stiffness changes across the Alzheimer's disease spectrum. NeuroImage: Clinical, 2016, 10, 283-290.	1.4	152
174	AVâ€1451 tau and Î²â€amyloid positron emission tomography imaging in dementia with Lewy bodies. Annals of Neurology, 2017, 81, 58-67.	2.8	152
175	Automatic quality assessment in structural brain magnetic resonance imaging. Magnetic Resonance in Medicine, 2009, 62, 365-372.	1.9	151
176	Factors affecting AÎ² plasma levels and their utility as biomarkers in ADNI. Acta Neuropathologica, 2011, 122, 401-13.	3.9	151
177	In Vivo Magnetic Resonance Microimaging of Individual Amyloid Plaques in Alzheimer's Transgenic Mice. Journal of Neuroscience, 2005, 25, 10041-10048.	1.7	150
178	Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology, 2011, 77, 1263-1271.	1.5	150
179	Association of brain amyloid-Î² with cerebral perfusion and structure in Alzheimerâ€™s disease and mild cognitive impairment. Brain, 2014, 137, 1550-1561.	3.7	150
180	Association of Excessive Daytime Sleepiness With Longitudinal Î²-Amyloid Accumulation in Elderly Persons Without Dementia. JAMA Neurology, 2018, 75, 672.	4.5	150

#	Article	IF	Citations
181	3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. NeuroImage, 2008, 41, 19-34.	2.1	149
182	Effect of lifestyle activities on alzheimer disease biomarkers and cognition. Annals of Neurology, 2012, 72, 730-738.	2.8	149
183	Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging. JAMA Neurology, 2017, 74, 1073.	4.5	149
184	Estimating longâ€term multivariate progression from shortâ€term data. Alzheimer's and Dementia, 2014, 10, S400-10.	0.4	148
185	Alzheimer Disease: Postmortem Neuropathologic Correlates of Antemortem¹H MR Spectroscopy Metabolite Measurements¹. Radiology, 2008, 248, 210-220.	3.6	147
186	APOE modifies the association between AÎ² load and cognition in cognitively normal older adults. Neurology, 2012, 78, 232-240.	1.5	147
187	MRI in the presurgical evaluation of patients with frontal lobe epilepsy and children with temporal lobe epilepsy: pathologic correlation and prognostic importance. Epilepsy Research, 1992, 11, 51-59.	0.8	146
188	Interleaved echo planar imaging on a standard MRI system. Magnetic Resonance in Medicine, 1994, 31, 67-72.	1.9	146
189	Rates of cerebral atrophy differ in different degenerative pathologies. Brain, 2006, 130, 1148-1158.	3.7	146
190	Functional Impact of White Matter Hyperintensities in Cognitively Normal Elderly Subjects. Archives of Neurology, 2010, 67, 1379-85.	4.9	146
191	Disrupted thalamocortical connectivity in PSP: A resting-state fMRI, DTI, and VBM study. Parkinsonism and Related Disorders, 2011, 17, 599-605.	1.1	146
192	Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology, 2012, 79, 1570-1577.	1.5	146
193	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurology, 2021, 78, 396.	4.5	146
194	Characterizing Alzheimer's disease using a hypometabolic convergence index. NeuroImage, 2011, 56, 52-60.	2.1	144
195	Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nature Reviews Neurology, 2021, 17, 580-589.	4.9	144
196	Dementia with Lewy bodies. Neurology, 2014, 83, 801-809.	1.5	143
197	Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA. Neurology, 2013, 81, 337-345.	1.5	142
198	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. Alzheimer's and Dementia, 2015, 11, 740-756.	0.4	142

#	Article	IF	Citations
199	Genome-wide analysis reveals novel genes influencing temporal lobe structure with relevance to neurodegeneration in Alzheimer's disease. NeuroImage, 2010, 51, 542-554.	2.1	141
200	Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4768-4773.	3.3	141
201	PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathologica, 2015, 129, 757-762.	3.9	139
202	Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiology of Aging, 2008, 29, 1285-1295.	1.5	138
203	A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology, 2017, 88, 1768-1775.	1.5	136
204	Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. Annals of Neurology, 2017, 82, 706-718.	2.8	136
205	[¹⁸F]AVâ€1451 tau positron emission tomography in progressive supranuclear palsy. Movement Disorders, 2017, 32, 124-133.	2.2	136
206	Comparative Diagnostic Utility of Different MR Modalities in Mild Cognitive Impairment and Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2002, 14, 198-207.	0.7	135
207	Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. Journal of Molecular Neuroscience, 2002, 19, 23-27.	1.1	135
208	Depressive Symptoms in Mild Cognitive Impairment Predict Greater Atrophy in Alzheimer's Disease-Related Regions. Biological Psychiatry, 2012, 71, 814-821.	0.7	135
209	Measurement of MRI scanner performance with the ADNI phantom. Medical Physics, 2009, 36, 2193-2205.	1.6	134
210	Diabetes and Elevated Hemoglobin A1c Levels Are Associated with Brain Hypometabolism but Not Amyloid Accumulation. Journal of Nuclear Medicine, 2014, 55, 759-764.	2.8	134
211	The evolution of primary progressive apraxia of speech. Brain, 2014, 137, 2783-2795.	3.7	134
212	Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. Cortex, 2015, 69, 220-236.	1.1	133
213	Heritability of Leukoaraiosis in Hypertensive Sibships. Hypertension, 2004, 43, 483-487.	1.3	132
214	Altered functional connectivity in asymptomatic MAPT subjects. Neurology, 2011, 77, 866-874.	1.5	132
215	Common variants at 12q15 and 12q24 are associated with infant head circumference. Nature Genetics, 2012, 44, 532-538.	9.4	130
216	Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: An ADNI study of 515 subjects. NeuroImage, 2009, 48, 668-681.	2.1	129

#	Article	IF	Citations
217	The bivariate distribution of amyloid-Î² and tau: relationship with established neurocognitive clinical syndromes. Brain, 2019, 142, 3230-3242.	3.7	129
218	Intensity non-uniformity correction using N3 on 3-T scanners with multichannel phased array coils. NeuroImage, 2008, 39, 1752-1762.	2.1	128
219	3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiology of Aging, 2010, 31, 1284-1303.	1.5	127
220	Common variants at 6q22 and 17q21 are associated with intracranial volume. Nature Genetics, 2012, 44, 539-544.	9.4	126
221	The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Frontiers in Aging Neuroscience, 2013, 5, 11.	1.7	126
222	White matter hyperintensities: relationship to amyloid and tau burden. Brain, 2019, 142, 2483-2491.	3.7	126
223	Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: Tissue-specific intensity normalization and parameter selection. NeuroImage, 2010, 50, 516-523.	2.1	125
224	Survey of Protocols for the Manual Segmentation of the Hippocampus: Preparatory Steps Towards a Joint EADC-ADNI Harmonized Protocol. Journal of Alzheimer's Disease, 2011, 26, 61-75.	1.2	125
225	Measuring the Characteristic Topography of Brain Stiffness with Magnetic Resonance Elastography. PLoS ONE, 2013, 8, e81668.	1.1	125
226	Rich club analysis in the Alzheimer's disease connectome reveals a relatively undisturbed structural core network. Human Brain Mapping, 2015, 36, 3087-3103.	1.9	125
227	Vascular Imaging Abnormalities and Cognition. Stroke, 2015, 46, 433-440.	1.0	125
228	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathologica, 2017, 133, 705-715.	3.9	125
229	Operative strategy in patients with MRI-identified dual pathology and temporal lobe epilepsy. Epilepsy Research, 1993, 14, 175-182.	0.8	124
230	Identification of Anonymous MRI Research Participants with Face-Recognition Software. New England Journal of Medicine, 2019, 381, 1684-1686.	13.9	124
231	Delphi definition of the EADCâ€ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance. Alzheimer's and Dementia, 2015, 11, 126-138.	0.4	123
232	Role of structural MRI in Alzheimer's disease. Alzheimer's Research and Therapy, 2010, 2, 23.	3.0	122
233	Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial. Revue Neurologique, 2013, 169, 737-743.	0.6	122
234	Tau PET in autosomal dominant Alzheimerâ€™s disease: relationship with cognition, dementia and other biomarkers. Brain, 2019, 142, 1063-1076.	3.7	122

#	Article	IF	Citations
235	Rates of Î²-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology, 2014, 82, 1605-1612.	1.5	119
236	Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain, 2011, 134, 1479-1492.	3.7	118
237	Quantitative MRI hippocampal volumes: association with onset and duration of epilepsy, and febrile convulsions in temporal lobectomy patients. Epilepsy Research, 1993, 15, 247-252.	0.8	117
238	Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy. Journal of Neuroscience, 2014, 34, 16247-16255.	1.7	117
239	GWAS of longitudinal amyloid accumulation on¹⁸F-florbetapir PET in Alzheimerâ€™s disease implicates microglial activation geneIL1RAP. Brain, 2015, 138, 3076-3088.	3.7	117
240	Prospective multiaxial motion correction for fMRI. Magnetic Resonance in Medicine, 2000, 43, 459-469.	1.9	116
241	Voxelwise gene-wide association study (vGeneWAS): Multivariate gene-based association testing in 731 elderly subjects. NeuroImage, 2011, 56, 1875-1891.	2.1	116
242	[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathologica, 2016, 132, 931-933.	3.9	116
243	Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. JAMA Neurology, 2018, 75, 970.	4.5	116
244	Quantitative magnetic resonance imaging phantoms: A review and the need for a system phantom. Magnetic Resonance in Medicine, 2018, 79, 48-61.	1.9	116
245	White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimerâ€™s disease. Brain, 2018, 141, 3065-3080.	3.7	116
246	Contrast optimization of fluid-attenuated inversion recovery (flair) imaging. Magnetic Resonance in Medicine, 1995, 34, 868-877.	1.9	114
247	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA Neurology, 2021, 78, 1108.	4.5	114
248	Performance of plasma phosphorylated tau 181 and 217 in the community. Nature Medicine, 2022, 28, 1398-1405.	15.2	114
249	Cardiovascular risk factors, cortisol, and amyloidâ€Î² deposition in Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2012, 8, 483-489.	0.4	113
250	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiology of Aging, 2015, 36, 452-461.	1.5	113
251	Tauâ€positron emission tomography correlates with neuropathology findings. Alzheimer's and Dementia, 2020, 16, 561-571.	0.4	113
252	Resting state functional MRI in Alzheimer's Disease. Alzheimer's Research and Therapy, 2012, 4, 2.	3.0	112

#	Article	IF	Citations
253	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1111.	4.5	112
254	Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness. Alzheimer's and Dementia, 2017, 13, 168-177.	0.4	110
255	Clinical Correlates of White Matter Tract Degeneration in Progressive Supranuclear Palsy. Archives of Neurology, 2011, 68, 753-60.	4.9	110
256	1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. Journal of the International Neuropsychological Society, 2002, 8, 934-942.	1.2	109
257	18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiology of Aging, 2014, 35, 2096-2106.	1.5	108
258	Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a populationâ€based elderly cohort. Alzheimer's and Dementia, 2016, 12, 1226-1234.	0.4	107
259	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. JAMA Neurology, 2017, 74, 718.	4.5	107
260	MR Findings in Normal-Pressure Hydrocephalus: Significance and Comparison with Other Forms of Dementia. Journal of Computer Assisted Tomography, 1987, 11, 923-931.	0.5	106
261	Prosodic and phonetic subtypes of primary progressive apraxia of speech. Brain and Language, 2018, 184, 54-65.	0.8	106
262	Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study. Brain, 2006, 129, 3103-3114.	3.7	105
263	Temporoparietal atrophy: A marker of AD pathology independent of clinical diagnosis. Neurobiology of Aging, 2011, 32, 1531-1541.	1.5	105
264	Training labels for hippocampal segmentation based on the EADCâ€ADNI harmonized hippocampal protocol. Alzheimer's and Dementia, 2015, 11, 175-183.	0.4	105
265	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurology, The, 2016, 15, 56-64.	4.9	104
266	Temporal Lobe Volume Measurement from MR Images. Journal of Computer Assisted Tomography, 1988, 12, 21-29.	0.5	103
267	Unbiased tensor-based morphometry: Improved robustness and sample size estimates for Alzheimer's disease clinical trials. NeuroImage, 2013, 66, 648-661.	2.1	103
268	Aspartate Mutations in Presenilin and Î³-Secretase Inhibitors Both Impair Notch1 Proteolysis and Nuclear Translocation with Relative Preservation of Notch1 Signaling. Journal of Neurochemistry, 2002, 75, 583-593.	2.1	101
269	Migraine and white matter hyperintensities. Neurology, 2013, 81, 1308-1313.	1.5	101
270	Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging. Neurology, 2015, 84, 1433-1442.	1.5	101

#	Article	IF	Citations
271	FDG PET and MRI in Logopenic Primary Progressive Aphasia versus Dementia of the Alzheimerâ€™s Type. PLoS ONE, 2013, 8, e62471.	1.1	100
272	Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease. Archives of Neurology, 2012, 69, 856-67.	4.9	99
273	Cerebral amyloid PET imaging in Alzheimerâ€™s disease. Acta Neuropathologica, 2013, 126, 643-657.	3.9	99
274	The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. Alzheimer's and Dementia, 2018, 14, 563-575.	0.4	98
275	Midlife systemic inflammatory markers are associated with late-life brain volume. Neurology, 2017, 89, 2262-2270.	1.5	97
276	Determination of 10â€“20 system electrode locations using magnetic resonance image scanning with markers. Electroencephalography and Clinical Neurophysiology, 1993, 86, 7-14.	0.3	96
277	MRI and MRS predictors of mild cognitive impairment in a population-based sample. Neurology, 2013, 81, 126-133.	1.5	95
278	Early Postmenopausal Transdermal 17Î²-Estradiol Therapy and Amyloid-Î² Deposition. Journal of Alzheimer's Disease, 2016, 53, 547-556.	1.2	94
279	The Significance of Atypia and Histologic Malignancy in Pilocytic Astrocytoma of the Cerebellum: A Clinicopathologic and Flow Cytometric Study. Journal of Child Neurology, 1994, 9, 301-310.	0.7	92
280	Real-time adaptive motion correction in functional MRI. Magnetic Resonance in Medicine, 1996, 36, 436-444.	1.9	92
281	Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. American Journal of Neuroradiology, 2003, 24, 843-9.	1.2	92
282	3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Human Brain Mapping, 2010, 31, 786-797.	1.9	91
283	Discovery and replication of gene influences on brain structure using LASSO regression. Frontiers in Neuroscience, 2012, 6, 115.	1.4	91
284	Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology, 2012, 79, 553-560.	1.5	91
285	Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. NeuroImage, 2011, 55, 522-531.	2.1	90
286	Harmonization of magnetic resonanceâ€based manual hippocampal segmentation: A mandatory step for wide clinical use. Alzheimer's and Dementia, 2011, 7, 171-174.	0.4	88
287	Alzheimer's disease: The next frontierâ€"Special Report 2017. Alzheimer's and Dementia, 2017, 13, 374-380.	0.4	88
288	Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimer's and Dementia, 2022, 18, 1128-1140.	0.4	88

#	Article	IF	Citations
289	Electrocorticography and Temporal Lobe Epilepsy: Relationship to Quantitative MRI and Operative Outcome. Epilepsia, 1995, 36, 692-696.	2.6	87
290	Significance of Cerebellar Atrophy in Intractable Temporal Lobe Epilepsy: A Quantitative MRI Study. Epilepsia, 2000, 41, 1315-1320.	2.6	87
291	Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 Î²-Amyloid Measures Across the Spectrum of Alzheimer Disease. JAMA Neurology, 2015, 72, 571.	4.5	87
292	Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia. Journal of Neurology, 2008, 255, 1302-8.	1.8	86
293	Caudate atrophy on MRI is a characteristic feature of FTLDâ€FUS. European Journal of Neurology, 2010, 17, 969-975.	1.7	86
294	Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women. Neurology, 2013, 80, 911-918.	1.5	86
295	Tauâ€PET uptake: Regional variation in average SUVR and impact of amyloid deposition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 21-30.	1.2	86
296	RASER: A new ultrafast magnetic resonance imaging method. Magnetic Resonance in Medicine, 2007, 58, 794-799.	1.9	85
297	Transforming cerebrospinal fluid AÎ²42 measures into calculated Pittsburgh compound B units of brain AÎ² amyloid. , 2011, 7, 133-141.		85
298	Performance of the CogState computerized battery in the Mayo ClinicÂStudy on Aging. Alzheimer's and Dementia, 2015, 11, 1367-1376.	0.4	85
299	Effects of hardware heterogeneity on the performance of SVM Alzheimer's disease classifier. NeuroImage, 2011, 58, 785-792.	2.1	84
300	Comparison of Pittsburgh compound B and florbetapir in crossâ€sectional and longitudinal studies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 180-190.	1.2	84
301	Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia. Neurobiology of Aging, 2015, 36, 1245-1252.	1.5	83
302	Midlife Systemic Inflammation, Late-Life White Matter Integrity, and Cerebral Small Vessel Disease. Stroke, 2017, 48, 3196-3202.	1.0	83
303	Voxel-Based Morphometry in Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions With and Without Progranulin Mutations. Archives of Neurology, 2007, 64, 371.	4.9	82
304	Association of Alzheimer's disease GWAS loci with MRI markers of brain aging. Neurobiology of Aging, 2015, 36, 1765.e7-1765.e16.	1.5	82
305	Progressive hippocampal atrophy in chronic intractable temporal lobe epilepsy. Annals of Neurology, 1999, 45, 526-529.	2.8	81
306	Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults. JAMA Neurology, 2017, 74, 801.	4.5	81

#	Article	IF	Citations
307	Diabetes, Prediabetes, and Brain Volumes and Subclinical Cerebrovascular Disease on MRI: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). Diabetes Care, 2017, 40, 1514-1521.	4.3	81
308	Progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a description of 55 cases and comparison to other phenotypes. Brain Communications, 2020, 2, fcaa068.	1.5	81
309	Methodological considerations for measuring rates of brain atrophy. Journal of Magnetic Resonance Imaging, 2003, 18, 16-24.	1.9	80
310	Quantitative magnetic resonance techniques as surrogate markers of Alzheimerâ€™s disease. NeuroRx, 2004, 1, 196-205.	6.0	80
311	Association of Ambulatory Blood Pressure With Ischemic Brain Injury. Hypertension, 2007, 49, 1228-1234.	1.3	80
312	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1005-1014.	0.4	80
313	Advances in neuroimaging of traumatic brain injury and posttraumatic stress disorder. Journal of Rehabilitation Research and Development, 2009, 46, 717.	1.6	80
314	Mapping Alzheimer's disease progression in 1309 MRI scans: Power estimates for different inter-scan intervals. NeuroImage, 2010, 51, 63-75.	2.1	79
315	Excessive daytime sleepiness and fatigue may indicate accelerated brain aging in cognitively normal late middle-aged and older adults. Sleep Medicine, 2017, 32, 236-243.	0.8	79
316	Preferential degradation of cognitive networks differentiates Alzheimerâ€™s disease from ageing. Brain, 2018, 141, 1486-1500.	3.7	79
317	Diffusion MRI Indices and Their Relation to Cognitive Impairment in Brain Aging: The Updated Multi-protocol Approach in ADNI3. Frontiers in Neuroinformatics, 2019, 13, 2.	1.3	79
318	Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects. NeuroImage, 2010, 51, 488-499.	2.1	78
319	A Quantitative Postmortem MRI Design Sensitive to White Matter Hyperintensity Differences and Their Relationship With Underlying Pathology. Journal of Neuropathology and Experimental Neurology, 2012, 71, 1113-1122.	0.9	78
320	PART and SNAP. Acta Neuropathologica, 2014, 128, 773-776.	3.9	78
321	Primary intracerebral malignant lymphoma: a clinicopathological study of 89 patients. Journal of Neurosurgery, 1995, 82, 558-566.	0.9	77
322	Real-time autoshimming for echo planar timecourse imaging. Magnetic Resonance in Medicine, 2002, 48, 771-780.	1.9	77
323	Accurate measurement of brain changes in longitudinal MRI scans using tensor-based morphometry. NeuroImage, 2011, 57, 5-14.	2.1	77
324	Magnetic resonance elastography of the brain in a mouse model of Alzheimer's disease: initial results. Magnetic Resonance Imaging, 2012, 30, 535-539.	1.0	77

#	Article	IF	Citations
325	Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathologica Communications, 2014, 2, 26.	2.4	77
326	Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 421.	0.4	77
327	A comparison of manual tracing and FreeSurfer for estimating hippocampal volume over the adult lifespan. Human Brain Mapping, 2018, 39, 2500-2513.	1.9	77
328	The Association of Long-Term Exposure to Particulate Matter Air Pollution with Brain MRI Findings: The ARIC Study. Environmental Health Perspectives, 2018, 126, 027009.	2.8	76
329	Hippocampal Volumes, Proton Magnetic Resonance Spectroscopy Metabolites, and Cerebrovascular Disease in Mild Cognitive Impairment Subtypes. Archives of Neurology, 2008, 65, 1621-8.	4.9	75
330	Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study. Journal of Nuclear Medicine, 2019, 60, 1611-1621.	2.8	75
331	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	3.7	74
332	Magnetic Resonance Imaging of Alzheimer's Pathology in the Brains of Living Transgenic Mice: A New Tool in Alzheimer's Disease Research. Neuroscientist, 2007, 13, 38-48.	2.6	73
333	Functional magnetic resonance imaging changes in amnestic and nonamnestic mild cognitive impairment during encoding and recognition tasks. Journal of the International Neuropsychological Society, 2009, 15, 372-382.	1.2	73
334	Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology, 2014, 82, 1959-1967.	1.5	73
335	[¹⁸F]AVâ€1451 tauâ€PET and primary progressive aphasia. Annals of Neurology, 2018, 83, 599-611.	2.8	73
336	Gender differences in post-temporal lobectomy verbal memory and relationships between MRI hippocampal volumes and preoperative verbal memory. Epilepsy Research, 1995, 20, 69-76.	0.8	72
337	The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. Brain, 2019, 142, 1134-1147.	3.7	72
338	Notch1 and Amyloid Precursor Protein Are Competitive Substrates for Presenilin1-dependent Î³-Secretase Cleavage. Journal of Biological Chemistry, 2001, 276, 30018-30023.	1.6	71
339	Comparisons Between Alzheimer Disease, Frontotemporal Lobar Degeneration, and Normal Aging With Brain Mapping. Topics in Magnetic Resonance Imaging, 2005, 16, 409-425.	0.7	71
340	Anatomical differences between CBSâ€corticobasal degeneration and CBSâ€Alzheimer's disease. Movement Disorders, 2010, 25, 1246-1252.	2.2	71
341	Effect of intellectual enrichment on AD biomarker trajectories. Neurology, 2016, 86, 1128-1135.	1.5	71
342	Common Genetic Variation Indicates Separate Causes for Periventricular and Deep White Matter Hyperintensities. Stroke, 2020, 51, 2111-2121.	1.0	71

#	Article	IF	Citations
343	Visual Hallucinations in Posterior Cortical Atrophy. Archives of Neurology, 2006, 63, 1427.	4.9	70
344	Argyrophilic grains: A distinct disease or an additive pathology?. Neurobiology of Aging, 2008, 29, 566-573.	1.5	70
345	Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimer's and Dementia, 2011, 7, 396-401.	0.4	70
346	Smoking and white matter hyperintensity progression. Neurology, 2015, 84, 841-848.	1.5	70
347	Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2017, 60, 92-103.	1.5	70
348	Sequential magnetic resonance imaging following stereotactic radiofrequency ventralis lateralis thalamotomy. Journal of Neurosurgery, 1991, 74, 579-584.	0.9	69
349	Ante mortem amyloid imaging and Î²-amyloid pathology in a case with dementia with Lewy bodies. Neurobiology of Aging, 2012, 33, 878-885.	1.5	69
350	Progranulin-associated PiB-negative logopenic primary progressive aphasia. Journal of Neurology, 2014, 261, 604-614.	1.8	69
351	Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration. JAMA Neurology, 2019, 76, 95.	4.5	69
352	Familial Frontotemporal Dementia Associated with a Novel Presenilin-1 Mutation. Dementia and Geriatric Cognitive Disorders, 2002, 14, 13-21.	0.7	68
353	Nonlinear time course of brain volume loss in cognitively normal and impaired elders. Neurobiology of Aging, 2012, 33, 845-855.	1.5	68
354	Amyloid-Î² deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain, 2016, 139, 2740-2750.	3.7	68
355	Entorhinal cortex tau, amyloid-Î², cortical thickness and memory performance in non-demented subjects. Brain, 2019, 142, 1148-1160.	3.7	68
356	Hippocampal Volume Is Associated with Memory but not Nonmemory Cognitive Performance in Patients with Mild Cognitive Impairment. Journal of Molecular Neuroscience, 2003, 20, 241-248.	1.1	67
357	Correlation Between Antemortem Magnetic Resonance Imaging Findings and Pathologically Confirmed Corticobasal Degeneration. Archives of Neurology, 2004, 61, 1881-4.	4.9	67
358	Associations of microalbuminuria with brain atrophy and white matter hyperintensities in hypertensive sibships. Journal of the Neurological Sciences, 2008, 271, 53-60.	0.3	67
359	The pattern of atrophy in familial Alzheimer disease. Neurology, 2013, 81, 1425-1433.	1.5	67
360	Obesity, Insulin Resistance, and Incident Small Vessel Disease on Magnetic Resonance Imaging. Stroke, 2015, 46, 3131-3136.	1.0	67

#	Article	IF	Citations
361	Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 214-227.	1.5	67
362	[¹⁸F]AVâ€1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. Annals of Neurology, 2018, 83, 248-257.	2.8	67
363	FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain, 2018, 141, 1201-1217.	3.7	67
364	Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensorâ€based morphometry. Human Brain Mapping, 2010, 31, 499-514.	1.9	66
365	Untreated Type 2 Diabetes and Its Complications Are Associated With Subcortical Infarctions. Diabetes Care, 2011, 34, 184-186.	4.3	66
366	Distinct regional anatomic and functional correlates of neurodegenerative apraxia of speech and aphasia: An MRI and FDG-PET study. Brain and Language, 2013, 125, 245-252.	0.8	66
367	Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. JAMA Neurology, 2019, 76, 187.	4.5	66
368	Selective Worsening of Brain Injury Biomarker Abnormalities in Cognitively Normal Elderly Persons With Î²-Amyloidosis. JAMA Neurology, 2013, 70, 1030.	4.5	65
369	Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2016, 53, 573-581.	1.2	65
370	Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology, 2016, 87, 2016-2025.	1.5	65
371	Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathologica, 2019, 137, 227-238.	3.9	65
372	Î²-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology, 2020, 94, e282-e291.	1.5	65
373	An fMRI study of somatosensory-implicated acupuncture points in stable somatosensory stroke patients. Journal of Magnetic Resonance Imaging, 2006, 24, 1018-1024.	1.9	64
374	Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain, 2012, 135, 2470-2477.	3.7	64
375	Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary report. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 177-188.	1.8	64
376	Comparison of amyloid plaque contrast generated by T₂â€weighted, Tâ€weighted, and susceptibilityâ€weighted imaging methods in transgenic mouse models of Alzheimer's disease. Magnetic Resonance in Medicine, 2009, 61, 1158-1164.	1.9	63
377	Magnetic resonance spectroscopy, Î²-amyloid load, and cognition in a population-based sample of cognitively normal older adults. Neurology, 2011, 77, 951-958.	1.5	63
378	Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge. NeuroImage, 2015, 123, 149-164.	2.1	63

#	Article	IF	Citations
379	Neuroimaging Correlates of Cerebral Microbleeds. Stroke, 2017, 48, 2964-2972.	1.0	63
380	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. NeuroImage, 2021, 224, 117433.	2.1	63
381	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39.	1.5	62
382	Î²-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology, 2020, 95, e3257-e3268.	1.5	62
383	Imaging Signatures of Molecular Pathology in Behavioral Variant Frontotemporal Dementia. Journal of Molecular Neuroscience, 2011, 45, 372-8.	1.1	61
384	MR Imaging Features of Amyloid-Related Imaging Abnormalities. American Journal of Neuroradiology, 2013, 34, 1958-1965.	1.2	61
385	Diffusion weighted imaging-based maximum density path analysis and classification of Alzheimer's disease. Neurobiology of Aging, 2015, 36, S132-S140.	1.5	61
386	Relationship between hippocampal atrophy and neuropathology markers: A 7T MRI validation study of the EADCâ€ADNI HarmonizedÂHippocampal Segmentation Protocol. Alzheimer's and Dementia, 2015, 11, 139-150.	0.4	61
387	Functional heterogeneity of the supplementary motor area. American Journal of Neuroradiology, 2005, 26, 1819-23.	1.2	61
388	Spontaneous decompression of syringomyelia: magnetic resonance imaging findings. Journal of Neurosurgery, 1991, 74, 283-286.	0.9	60
389	Comparison of Imaging Biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging. Archives of Neurology, 2012, 69, 614.	4.9	60
390	Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia. American Journal of Geriatric Psychiatry, 2016, 24, 126-135.	0.6	60
391	Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 167-182.e1.	1.5	60
392	In vivo ¹⁸ F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology, 2018, 90, e947-e954.	1.5	60
393	Intractable frontal lobe epilepsy: Pathological and MRI features. Epilepsy Research, 1995, 20, 171-178.	0.8	59
394	Maximizing power to track Alzheimer's disease and MCI progression by LDA-based weighting of longitudinal ventricular surface features. NeuroImage, 2013, 70, 386-401.	2.1	59
395	Focal hemosiderin deposits and Î²â€amyloid load in the ADNI cohort. Alzheimer's and Dementia, 2013, 9, S116-23.	0.4	59
396	Lifeâ€course blood pressure in relation to brain volumes. Alzheimer's and Dementia, 2016, 12, 890-899.	0.4	59

#	Article	IF	Citations
397	Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. NeuroImage, 2017, 144, 113-127.	2.1	59
398	The association of mid-to late-life systemic inflammation with white matter structure in older adults: The Atherosclerosis Risk in Communities Study. Neurobiology of Aging, 2018, 68, 26-33.	1.5	59
399	Central Arterial Stiffness Is Associated With Structural Brain Damage and Poorer Cognitive Performance: The ARIC Study. Journal of the American Heart Association, 2019, 8, e011045.	1.6	59
400	A prospective approach to correct for inter-image head rotation in FMRI. Magnetic Resonance in Medicine, 1998, 39, 234-243.	1.9	58
401	MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies. Neurology, 2013, 81, 1681-1689.	1.5	58
402	Atrial fibrillation, cognitive impairment, and neuroimaging. Alzheimer's and Dementia, 2016, 12, 391-398.	0.4	58
403	White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia. JAMA Neurology, 2014, 71, 1547.	4.5	57
404	Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. Neurology, 2018, 90, e1404-e1412.	1.5	57
405	Symmetric corticobasal degeneration (S-CBD). Parkinsonism and Related Disorders, 2010, 16, 208-214.	1.1	56
406	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 824-857.	0.4	56
407	Longitudinal characterization of two siblings with frontotemporal dementia and parkinsonism linked to chromosome 17 associated with the S305N tau mutation. Brain, 2005, 128, 752-772.	3.7	55
408	AÎ² Imaging: feasible, pertinent, and vital to progress in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 209-219.	3.3	55
409	Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. Neurology, 2018, 90, e466-e473.	1.5	55
410	Comparison of phantom and registration scaling corrections using the ADNI cohort. NeuroImage, 2009, 47, 1506-1513.	2.1	54
411	Frontal asymmetry in behavioral variant frontotemporal dementia: clinicoimaging and pathogenetic correlates. Neurobiology of Aging, 2013, 34, 636-639.	1.5	54
412	Midlife and Lateâ€Life Vascular Risk Factors and White Matter Microstructural Integrity: The Atherosclerosis Risk in Communities Neurocognitive Study. Journal of the American Heart Association, 2017, 6, .	1.6	54
413	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. NeuroImage: Clinical, 2019, 23, 101823.	1.4	54
414	Cortical Î²-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging. Translational Psychiatry, 2019, 9, 123.	2.4	54

#	Article	IF	Citations
415	Ventricular maps in 804 ADNI subjects: correlations with CSF biomarkers and clinical decline. Neurobiology of Aging, 2010, 31, 1386-1400.	1.5	53
416	Quantitative neurofibrillary tangle density and brain volumetric MRI analyses in Alzheimerâ€™s disease presenting as logopenic progressive aphasia. Brain and Language, 2013, 127, 127-134.	0.8	53
417	Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease. Human Brain Mapping, 2019, 40, 1618-1631.	1.9	53
418	Cerebral microbleeds. Neurology, 2019, 92, e253-e262.	1.5	53
419	Frontotemporal Lobar Degeneration Without Lobar Atrophy. Archives of Neurology, 2006, 63, 1632.	4.9	52
420	Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease. NeuroImage, 2008, 39, 1034-1040.	2.1	52
421	Homocysteine effects on brain volumes mapped in 732 elderly individuals. NeuroReport, 2011, 22, 391-395.	0.6	52
422	Discovery and replication of dopamine-related gene effects on caudate volume in young and elderly populations (N=1198) using genome-wide search. Molecular Psychiatry, 2011, 16, 927-937.	4.1	52
423	Targeting Vascular Amyloid in Arterioles of Alzheimer Disease Transgenic Mice With Amyloid Î² Protein Antibody-Coated Nanoparticles. Journal of Neuropathology and Experimental Neurology, 2011, 70, 653-661.	0.9	52
424	Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. International Psychogeriatrics, 2018, 30, 245-251.	0.6	52
425	A brief history of â€œAlzheimer diseaseâ€• Neurology, 2019, 92, 1053-1059.	1.5	52
426	Deep learning-based brain age prediction in normal aging and dementia. Nature Aging, 2022, 2, 412-424.	5.3	52
427	Emerging Î²-Amyloid Pathology and Accelerated Cortical Atrophy. JAMA Neurology, 2014, 71, 725.	4.5	51
428	Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2014, 10, S226-35.	0.4	51
429	Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals. Annals of Neurology, 2017, 81, 871-882.	2.8	51
430	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimerâ€™s disease. PLoS ONE, 2018, 13, e0195838.	1.1	51
431	The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. Neurobiology of Aging, 2019, 77, 26-36.	1.5	51
432	Longitudinal neuroimaging biomarkers differ across Alzheimerâ€™s disease phenotypes. Brain, 2020, 143, 2281-2294.	3.7	51

#	Article	IF	Citations
433	Detection of Î²-amyloid positivity in Alzheimerâ€™s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Communications, 2021, 3, fcab008.	1.5	51
434	Selective Posterior Cerebral Artery Injection of Amytal: New Method of Preoperative Memory Testing. Mayo Clinic Proceedings, 1989, 64, 965-975.	1.4	50
435	Alliance for Aging Research AD Biomarkers Work Group: structural MRI. Neurobiology of Aging, 2011, 32, S48-S57.	1.5	50
436	Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: Determining sample size for treatment trials. Parkinsonism and Related Disorders, 2012, 18, 252-256.	1.1	49
437	Identification of an atypical variant of logopenic progressive aphasia. Brain and Language, 2013, 127, 139-144.	0.8	49
438	Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. Parkinsonism and Related Disorders, 2014, 20, 493-498.	1.1	49
439	Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. Brain and Language, 2015, 142, 45-53.	0.8	49
440	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. Annals of Neurology, 2018, 84, 705-716.	2.8	49
441	Protective variant for hippocampal atrophy identified by whole exome sequencing. Annals of Neurology, 2015, 77, 547-552.	2.8	48
442	Operationalizing protocol differences for EADCâ€ADNI manual hippocampal segmentation. Alzheimer's and Dementia, 2015, 11, 184-194.	0.4	48
443	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. Alzheimer's and Dementia, 2019, 15, 927-939.	0.4	48
444	A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR. Journal of Alzheimer's Disease, 2019, 67, 181-195.	1.2	48
445	MRI Correlates of Protein Deposition and Disease Severity in Postmortem Frontotemporal Lobar Degeneration. Neurodegenerative Diseases, 2009, 6, 106-117.	0.8	47
446	Amyloid pathway-based candidate gene analysis of [11C]PiB-PET in the Alzheimerâ€™s Disease Neuroimaging Initiative (ADNI) cohort. Brain Imaging and Behavior, 2012, 6, 1-15.	1.1	47
447	Head trauma and in vivo measures of amyloid and neurodegeneration in a population-based study. Neurology, 2014, 82, 70-76.	1.5	47
448	Effects of hormone therapy on brain structure. Neurology, 2016, 87, 887-896.	1.5	47
449	Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status. Clinical Neuropsychologist, 2017, 31, 99-117.	1.5	47
450	Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression. JAMA Psychiatry, 2022, 79, 464.	6.0	47

#	Article	IF	Citations
451	Therapeutic Embolization Angiography for Extra-Axial Lesions in the Head. Mayo Clinic Proceedings, 1986, 61, 427-441.	1.4	46
452	Transient postictal magnetic resonance imaging abnormality of the corpus callosum in a patient with epilepsy. Journal of Neurosurgery, 2002, 97, 714-717.	0.9	46
453	Voxelâ€based morphometry in patients with obsessiveâ€compulsive behaviors in behavioral variant frontotemporal dementia. European Journal of Neurology, 2012, 19, 911-917.	1.7	46
454	Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI. Neurology, 2013, 80, 2130-2137.	1.5	46
455	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. NeuroImage: Clinical, 2020, 25, 102152.	1.4	46
456	Selective Contrast Enhancement of Individual Alzheimerâ€™s Disease Amyloid Plaques Using a Polyamine and Gd-DOTA Conjugated Antibody Fragment Against Fibrillar AÎ²42 for Magnetic Resonance Molecular Imaging. Pharmaceutical Research, 2008, 25, 1861-1872.	1.7	45
457	Predicting functional decline in behavioural variant frontotemporal dementia. Brain, 2011, 134, 432-448.	3.7	45
458	Angular versus spatial resolution trade-offs for diffusion imaging under time constraints. Human Brain Mapping, 2013, 34, 2688-2706.	1.9	45
459	The Effect of Subsyndromal Symptoms of Depression and White Matter Lesions on Disability for Individuals with Mild Cognitive Impairment. American Journal of Geriatric Psychiatry, 2013, 21, 906-914.	0.6	45
460	Antemortem MRI findings associated with microinfarcts at autopsy. Neurology, 2014, 82, 1951-1958.	1.5	45
461	ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease. NeuroImage: Clinical, 2014, 4, 461-472.	1.4	45
462	Influence of amyloid and APOE on cognitive performance in a late middleâ€aged cohort. Alzheimer's and Dementia, 2016, 12, 281-291.	0.4	45
463	Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 62, 1713-1724.	1.2	45
464	Association of Brain Magnetic Resonance Imaging Signs With Cognitive Outcomes in Persons With Nonimpaired Cognition and Mild Cognitive Impairment. JAMA Network Open, 2019, 2, e193359.	2.8	45
465	Protein contributions to brain atrophy acceleration in Alzheimerâ€™s disease and primary age-related tauopathy. Brain, 2020, 143, 3463-3476.	3.7	45
466	Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?. NeuroImage: Clinical, 2013, 2, 249-257.	1.4	44
467	Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment. Neurology, 2016, 87, 2317-2323.	1.5	44
468	Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimerâ€™s Disease. Cerebral Cortex, 2021, 31, 1693-1706.	1.6	44

#	Article	IF	Citations
469	A standard system phantom for magnetic resonance imaging. Magnetic Resonance in Medicine, 2021, 86, 1194-1211.	1.9	44
470	Gray matter correlates of behavioral severity in progressive supranuclear palsy. Movement Disorders, 2011, 26, 493-498.	2.2	43
471	Fat-mass-related hormone, plasma leptin, predicts brain volumes in the elderly. NeuroReport, 2013, 24, 58-62.	0.6	43
472	Multipleâ€dose ponezumab for mildâ€toâ€moderate Alzheimer's disease: Safety and efficacy. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 339-347.	1.8	43
473	Accelerated functional brain aging in pre-clinical familial Alzheimerâ€™s disease. Nature Communications, 2021, 12, 5346.	5.8	43
474	Genomic Susceptibility Loci for Brain Atrophy in Hypertensive Sibships From the GENOA Study. Hypertension, 2005, 45, 793-798.	1.3	42
475	Common MRI acquisition non-idealities significantly impact the output of the boundary shift integral method of measuring brain atrophy on serial MRI. NeuroImage, 2006, 30, 1196-1202.	2.1	42
476	Identifying Cognitively Healthy Elderly Individuals with Subsequent Memory Decline by Using Automated MR Temporoparietal Volumes. Radiology, 2011, 259, 844-851.	3.6	42
477	Patterns of Brain Atrophy in Clinical Variants of Frontotemporal Lobar Degeneration. Dementia and Geriatric Cognitive Disorders, 2013, 35, 34-50.	0.7	42
478	Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiology of Aging, 2014, 35, 614-622.	1.5	42
479	Memory, executive, and multidomain subtle cognitive impairment. Neurology, 2015, 85, 144-153.	1.5	42
480	The Brain in Kidney Disease (BRINK) Cohort Study: Design and Baseline Cognitive Function. American Journal of Kidney Diseases, 2016, 67, 593-600.	2.1	42
481	Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. Cortex, 2018, 99, 358-374.	1.1	42
482	Longitudinal structural and molecular neuroimaging in agrammatic primary progressive aphasia. Brain, 2018, 141, 302-317.	3.7	42
483	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: AÂserial magnetic resonance imaging study. Alzheimer's and Dementia, 2018, 14, 43-53.	0.4	42
484	Bilateral Magnetic Resonance Imaging-Determined Hippocampal Atrophy and Verbal Memory Before and After Temporal Lobectomy. Epilepsia, 1996, 37, 526-533.	2.6	41
485	Imaging the Alzheimer Brain. Journal of Alzheimer's Disease, 2011, 26, 1-27.	1.2	41
486	Harmonized benchmark labels of the hippocampus on magnetic resonance: The EADCâ€ADNI project. Alzheimer's and Dementia, 2015, 11, 151.	0.4	41

#	Article	IF	Citations
487	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 257-266.	0.4	41
488	Cerebral Amyloid Deposition Is Associated with Gait Parameters in the Mayo Clinic Study of Aging. Journal of the American Geriatrics Society, 2017, 65, 792-799.	1.3	41
489	Association of Apolipoprotein E É›4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults. JAMA Network Open, 2019, 2, e1913909.	2.8	41
490	Late-Life Depression Is Associated With Reduced Cortical Amyloid Burden: Findings From the Alzheimerâ€™s Disease Neuroimaging Initiative Depression Project. Biological Psychiatry, 2021, 89, 757-765.	0.7	41
491	Anatomic correlates of stereotypies in frontotemporal lobar degeneration. Neurobiology of Aging, 2008, 29, 1859-1863.	1.5	40
492	Alzheimer's disease disrupts rich club organization in brain connectivity networks. , 2013, , 266-269.		40
493	Prevalence and Natural History of Superficial Siderosis. Stroke, 2017, 48, 3210-3214.	1.0	40
494	Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging. Annals of Neurology, 2019, 86, 866-877.	2.8	40
495	Association of common genetic variants with brain microbleeds. Neurology, 2020, 95, e3331-e3343.	1.5	40
496	Complexity in the genetic architecture of leukoaraiosis in hypertensive sibships from the GENOA Study. BMC Medical Genomics, 2009, 2, 16.	0.7	39
497	MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials. Neurobiology of Aging, 2016, 37, 26-37.	1.5	39
498	3<scp>D</scp> tractâ€specific local and global analysis of white matter integrity in <scp>A</scp>lzheimer's disease. Human Brain Mapping, 2017, 38, 1191-1207.	1.9	39
499	Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity. Stroke, 2019, 50, 3037-3044.	1.0	39
500	Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease. NeuroImage, 2015, 113, 61-69.	2.1	38
501	The biomarker-based diagnosis of Alzheimer's disease. 2â€"lessons from oncology. Neurobiology of Aging, 2017, 52, 141-152.	1.5	38
502	Comparison of variables associated with cerebrospinal fluid neurofilament, totalâ€tau, and neurogranin. Alzheimer's and Dementia, 2019, 15, 1437-1447.	0.4	38
503	Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition. Brain Communications, 2021, 3, fcab106.	1.5	38
504	Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular alternatives. NeuroImage, 2021, 231, 117845.	2.1	38

#	Article	IF	Citations
505	A deep learning framework identifies dimensional representations of Alzheimerâ€™s Disease from brain structure. Nature Communications, 2021, 12, 7065.	5.8	38
506	The Management of Intraosseous Arteriovenous Malformations in the Head and Neck Area. Plastic and Reconstructive Surgery, 1989, 84, 47-54.	0.7	37
507	Corticospinal tract degeneration associated with TDP-43 type C pathology and semantic dementia. Brain, 2013, 136, 455-470.	3.7	37
508	Effects of aerobic exercise on cognition and hippocampal volume in Alzheimerâ€™s disease: study protocol of a randomized controlled trial (The FIT-AD trial). Trials, 2014, 15, 394.	0.7	37
509	Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size. Neurobiology of Aging, 2014, 35, 808-818.	1.5	37
510	The transitional association between Î²â€amyloid pathology and regional brain atrophy. Alzheimer's and Dementia, 2015, 11, 1171-1179.	0.4	37
511	White Matter Reference Region in PET Studies of ¹¹C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid-Î² Deposition. Journal of Nuclear Medicine, 2018, 59, 1583-1589.	2.8	37
512	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain, 2019, 142, 3621-3635.	3.7	37
513	Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau. Brain Communications, 2020, 2, fcaa025.	1.5	37
514	APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. Science Translational Medicine, 2021, 13, eabc9375.	5.8	37
515	Sleep Apnea, Sleep Duration and Brain MRI Markers of Cerebral Vascular Disease and Alzheimerâ€™s Disease: The Atherosclerosis Risk in Communities Study (ARIC). PLoS ONE, 2016, 11, e0158758.	1.1	37
516	Family-based association study of matrix metalloproteinase-3 and -9 haplotypes with susceptibility to ischemic white matter injury. Human Genetics, 2007, 120, 671-680.	1.8	36
517	Modeling trajectories of regional volume loss in progressive supranuclear palsy. Movement Disorders, 2013, 28, 1117-1124.	2.2	36
518	Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309493.	0.9	36
519	Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures. Neurology, 2015, 84, 729-737.	1.5	36
520	Disrupted functional connectivity in primary progressive apraxia of speech. NeuroImage: Clinical, 2018, 18, 617-629.	1.4	36
521	The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 675-685.	0.4	36
522	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiology of Aging, 2015, 36, 2010-2017.	1.5	35

#	Article	IF	Citations
523	FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2016, 53, 1609-1616.	1.2	35
524	Acute pressure changes in the brain are correlated with MR elastography stiffness measurements: initial feasibility in an in vivo large animal model. Magnetic Resonance in Medicine, 2018, 79, 1043-1051.	1.9	35
525	Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1976-1987.	0.4	35
526	MR Microimaging of amyloid plaques in Alzheimerâ€™s disease transgenic mice. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 82-88.	3.3	34
527	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 739-749.	1.4	34
528	Pâ€tau/AÎ²42 and AÎ²42/40 ratios in CSF are equally predictive of amyloid PET status. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12190.	1.2	34
529	The Longitudinal Earlyâ€onset Alzheimer's Disease Study (LEADS): Framework and methodology. Alzheimer's and Dementia, 2021, 17, 2043-2055.	0.4	34
530	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. Nature Communications, 2021, 12, 3452.	5.8	34
531	Cognitive processing in Chinese literate and illiterate subjects: An fMRI study. Human Brain Mapping, 2006, 27, 144-152.	1.9	33
532	Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain. NeuroImage, 2011, 54, 113-122.	2.1	33
533	Robustness of automated hippocampal volumetry across magnetic resonance field strengths and repeat images. Alzheimer's and Dementia, 2014, 10, 430.	0.4	33
534	[P2â€“415]: THE MAYO CLINIC ADULT LIFESPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFESPAN. Alzheimer's and Dementia, 2017, 13, P792.	0.4	33
535	18F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus. NeuroImage: Clinical, 2018, 18, 897-902.	1.4	33
536	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. Brain, 2019, 142, 2466-2482.	3.7	33
537	MRI Outperforms [18F]AVâ€1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 105-113.	2.2	33
538	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. Molecular Neurodegeneration, 2020, 15, 57.	4.4	33
539	Mayo Normative Studies: Regression-Based Normative Data for the Auditory Verbal Learning Test for Ages 30â€“91 Years and the Importance of Adjusting for Sex. Journal of the International Neuropsychological Society, 2021, 27, 211-226.	1.2	33
540	Default Mode Network Disruption Secondary to a Lesion in the Anterior Thalamus. Archives of Neurology, 2011, 68, 242-7.	4.9	32

#	Article	IF	Citations
541	Mapping ventricular expansion onto cortical gray matter in older adults. Neurobiology of Aging, 2015, 36, S32-S41.	1.5	32
542	MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. Alzheimer's and Dementia, 2016, 12, 1297-1304.	0.4	32
543	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. Movement Disorders, 2016, 31, 989-994.	2.2	32
544	Association of white matter microstructural integrity with cognition and dementia. Neurobiology of Aging, 2019, 83, 63-72.	1.5	32
545	Predicting Progression to Mild Cognitive Impairment. Annals of Neurology, 2019, 85, 155-160.	2.8	32
546	Sensitivityâ€"Specificity of Tau and Amyloid Î² Positron Emission Tomography in Frontotemporal Lobar Degeneration. Annals of Neurology, 2020, 88, 1009-1022.	2.8	32
547	A computational model of neurodegeneration in Alzheimerâ€™s disease. Nature Communications, 2022, 13, 1643.	5.8	32
548	Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimer's Research and Therapy, 2021, 13, 199.	3.0	32
549	Field Strength in Neuro-MR Imaging. Journal of Computer Assisted Tomography, 1990, 14, 505-513.	0.5	31
550	Diet supplement CoQ₁₀ delays brain atrophy in aged transgenic mice with mutations in the amyloid precursor protein: An in vivo volume MRI study. BioFactors, 2008, 32, 169-178.	2.6	31
551	APOE Îµ4 influences Î²â€amyloid deposition in primary progressive aphasia and speech apraxia. Alzheimer's and Dementia, 2014, 10, 630-636.	0.4	31
552	Connectivity network measures predict volumetric atrophy in mild cognitive impairment. Neurobiology of Aging, 2015, 36, S113-S120.	1.5	31
553	Fractional anisotropy derived from the diffusion tensor distribution function boosts power to detect Alzheimer's disease deficits. Magnetic Resonance in Medicine, 2017, 78, 2322-2333.	1.9	31
554	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. NeuroImage: Clinical, 2018, 19, 939-947.	1.4	31
555	Cerebral microbleed incidence, relationship to amyloid burden. Neurology, 2020, 94, e190-e199.	1.5	31
556	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. Neurobiology of Disease, 2020, 142, 104960.	2.1	31
557	<scp>NIAâ€AA</scp> Alzheimer's Disease Framework: Clinical Characterization of Stages. Annals of Neurology, 2021, 89, 1145-1156.	2.8	31
558	Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimerâ€™s amyloid, tau and FDG PET status. Translational Psychiatry, 2021, 11, 585.	2.4	31

#	Article	IF	Citations
559	Magnetic Resonance Imaging in Epilepsy. Mayo Clinic Proceedings, 1996, 71, 695-711.	1.4	30
560	Rates of cerebral atrophy in autopsy-confirmed progressive supranuclear palsy. Annals of Neurology, 2006, 59, 200-203.	2.8	30
561	Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. Neurobiology of Aging, 2015, 36, 273-282.	1.5	30
562	Association of Kidney Function Biomarkers with Brain MRI Findings: The BRINK Study. Journal of Alzheimer's Disease, 2016, 55, 1069-1082.	1.2	30
563	LRRK2 variation and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2016, 31, 98-103.	1.1	30
564	Predicting clinical decline in progressive agrammatic aphasia and apraxia of speech. Neurology, 2017, 89, 2271-2279.	1.5	30
565	Longitudinal Association Between Brain Amyloid-Beta and Gait in the Mayo Clinic Study of Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 1244-1250.	1.7	30
566	Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. Mayo Clinic Proceedings, 2020, 95, 1195-1205.	1.4	30
567	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimerâ€™s Disease. Biological Psychiatry, 2021, 89, 776-785.	0.7	30
568	Comparison of [18 F]Flutemetamol and [11 C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals. NeuroImage: Clinical, 2017, 16, 295-302.	1.4	30
569	Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12291.	1.2	30
570	Popliteal Venous Aneurysm as a Source of Pulmonary Emboli in a Male: Case Report. Angiology, 1984, 35, 54-57.	0.8	29
571	Hippocampal Atrophy Correlates With Clinical Features of Alzheimer Disease in African Americans. Archives of Neurology, 2001, 58, 1593.	4.9	29
572	Common folate gene variant, MTHFR C677T, is associated with brain structure in two independent cohorts of people with mild cognitive impairment. NeuroImage: Clinical, 2012, 1, 179-187.	1.4	29
573	Early Indications of Future Cognitive Decline: Stable versus Declining Controls. PLoS ONE, 2013, 8, e74062.	1.1	29
574	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiology of Aging, 2014, 35, 1483-1490.	1.5	29
575	Low Plasma ApoE Levels Are Associated with Smaller Hippocampal Size in the Alzheimer's Disease Neuroimaging Initiative Cohort. Dementia and Geriatric Cognitive Disorders, 2015, 39, 154-166.	0.7	29
576	A robust biomarker of largeâ€scale network failure in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 152-161.	1.2	29

#	Article	IF	Citations
577	Decreased Glutamate Levels in Patients with Amnestic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiBâ€PET Study. Journal of Neuroimaging, 2017, 27, 630-636.	1.0	29
578	Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia. Brain and Language, 2019, 197, 104676.	0.8	29
579	Automated detection of imaging features of disproportionately enlarged subarachnoid space hydrocephalus using machine learning methods. NeuroImage: Clinical, 2019, 21, 101605.	1.4	29
580	KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimerâ€™s disease. Nature Communications, 2021, 12, 3825.	5.8	29
581	Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease. JAMA Neurology, 2022, 79, 592.	4.5	29
582	Wisconsin Card Sorting Test performance before and after temporal lobectomy. Journal of Epilepsy, 1994, 7, 313-317.	0.4	28
583	Elevated occipital Î²-amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1357-1364.	0.9	28
584	A commonly carried genetic variant in the delta opioid receptor gene, OPRD1, is associated with smaller regional brain volumes: Replication in elderly and young populations. Human Brain Mapping, 2014, 35, 1226-1236.	1.9	28
585	Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimerâ€™s disease. BMC Medical Genomics, 2017, 10, 29.	0.7	28
586	Association between white matter hyperintensities, cortical volumes, and late-onset epilepsy. Neurology, 2019, 92, e988-e995.	1.5	28
587	A Bayesian Approach to Multistate Hidden Markov Models: Application to Dementia Progression. Journal of the American Statistical Association, 2020, 115, 16-31.	1.8	28
588	Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly. Neurology, 2020, 94, e1793-e1802.	1.5	28
589	Detection of Alzheimer's disease amyloid beta 1â€42, pâ€tau, and tâ€tau assays. Alzheimer's and Dementia, 2022, 18, 635-644.	0.4	28
590	T1-Weighted MR imaging of the brain using a fast inversion recovery pulse sequence. Journal of Magnetic Resonance Imaging, 1996, 6, 356-362.	1.9	27
591	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimerâ€™s Disease: A Diffusion Tensor Imaging Study. Journal of Alzheimer's Disease, 2015, 49, 633-643.	1.2	27
592	Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. Parkinsonism and Related Disorders, 2015, 21, 1101-1104.	1.1	27
593	Multimorbidity and neuroimaging biomarkers among cognitively normal persons. Neurology, 2016, 86, 2077-2084.	1.5	27
594	Joint associations of Î²-amyloidosis and cortical thickness with cognition. Neurobiology of Aging, 2018, 65, 121-131.	1.5	27

#	Article	IF	Citations
595	Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2018, 48, 3-9.	1.1	27
596	Reduced fractional anisotropy of the genu of the corpus callosum as a cerebrovascular disease marker and predictor of longitudinal cognition in MCI. Neurobiology of Aging, 2020, 96, 176-183.	1.5	27
597	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. Neurology, 2020, 95, e23-e34.	1.5	27
598	Association of Initial Î²-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. JAMA Neurology, 2021, 78, 217.	4.5	27
599	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. NeuroImage: Clinical, 2021, 31, 102754.	1.4	27
600	Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease. NeuroImage, 2022, 256, 119228.	2.1	27
601	Effect of PS1 deficiency and an APP Î³-secretase inhibitor on Notch1 signaling in primary mammalian neurons. Molecular Brain Research, 2001, 87, 166-174.	2.5	26
602	Very Early Semantic Dementia With Progressive Temporal Lobe Atrophy. Archives of Neurology, 2008, 65, 1659-63.	4.9	26
603	Impact of apolipoprotein É›4-cerebrospinal fluid beta-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. , 2011, 7, 514-520.		26
604	Genome-wide association identifies genetic variants associated with lentiform nucleus volume in Nâ€‰=â€‰1345 young and elderly subjects. Brain Imaging and Behavior, 2013, 7, 102-115.	1.1	26
605	The Metabolic Syndrome and Cognitive Decline in the Atherosclerosis Risk in Communities Study (ARIC). Dementia and Geriatric Cognitive Disorders, 2014, 38, 337-346.	0.7	26
606	Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. Alzheimer's and Dementia, 2014, 10, 779-789.	0.4	26
607	Serum cholesterol and variant in cholesterol-related gene CETP predict white matter microstructure. Neurobiology of Aging, 2014, 35, 2504-2513.	1.5	26
608	Contributions of imprecision in <scp>PET</scp>â€<scp>MRI</scp> rigid registration to imprecision in amyloid <scp>PET</scp><scp>SUVR</scp> measurements. Human Brain Mapping, 2017, 38, 3323-3336.	1.9	26
609	Patterns of Neuropsychological Dysfunction and Cortical Volume Changes in Logopenic Aphasia. Journal of Alzheimer's Disease, 2018, 66, 1015-1025.	1.2	26
610	An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant. Movement Disorders Clinical Practice, 2019, 6, 452-461.	0.8	26
611	¹⁸Fâ€AVâ€1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. Movement Disorders, 2019, 34, 344-352.	2.2	26
612	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. Brain, 2021, 144, 3212-3225.	3.7	26

#	Article	IF	Citations
613	Sex differences in the relationship between visual memory and MRI hippocampal volumes.. Neuropsychology, 1996, 10, 343-351.	1.0	25
614	Time-to-event voxel-based techniques to assess regional atrophy associated with MCI risk of progression to AD. NeuroImage, 2011, 54, 985-991.	2.1	25
615	Clinical Characterization of a Kindred With a Novel 12-Octapeptide Repeat Insertion in the Prion Protein Gene. Archives of Neurology, 2011, 68, 1165.	4.9	25
616	Feature selection improves the accuracy of classifying Alzheimer disease using diffusion tensor images. , 2015, 2015, 126-130.		25
617	Neurocognition in individuals with incidentally-identified meningioma. Journal of Neuro-Oncology, 2017, 134, 125-132.	1.4	25
618	Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimerâ€™s Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 76, 261-274.	1.2	25
619	Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. Frontiers in Aging Neuroscience, 2019, 11, 355.	1.7	25
620	Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging. American Journal of Geriatric Psychiatry, 2021, 29, 179-191.	0.6	25
621	Gadoliniumâ€DTPAâ€enhanced magnetic resonance imaging in intractable partial epilepsy. Neurology, 1989, 39, 1115-1115.	1.5	25
622	Magnetic Resonance Imaging of Facial Vascular Anomalies. Mayo Clinic Proceedings, 1992, 67, 739-747.	1.4	24
623	HarP: The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation. A standard of reference from a global working group. Alzheimer's and Dementia, 2015, 11, 107-110.	0.4	24
624	MRS in Mild Cognitive Impairment: Early Differentiation of Dementia with Lewy Bodies and Alzheimer's Disease. Journal of Neuroimaging, 2015, 25, 269-274.	1.0	24
625	Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not aÂHomogeneous Clinical Entity. Journal of Alzheimer's Disease, 2016, 55, 1019-1029.	1.2	24
626	Aortic hemodynamics and white matter hyperintensities in normotensive postmenopausal women. Journal of Neurology, 2017, 264, 938-945.	1.8	24
627	Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. Neurology, 2018, 90, e940-e946.	1.5	24
628	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. NeuroImage, 2021, 238, 118259.	2.1	24
629	Genomic Susceptibility Loci for Brain Atrophy, Ventricular Volume, and Leukoaraiosis in Hypertensive Sibships. Archives of Neurology, 2009, 66, 847-57.	4.9	23
630	Predicting temporal lobe volume on MRI from genotypes using L¹-L² regularized regression. , 2012, , 1160-1163.		23

#	Article	IF	Citations
631	Multilocus genetic profiling to empower drug trials and predict brain atrophy. NeuroImage: Clinical, 2013, 2, 827-835.	1.4	23
632	Establishing Magnetic Resonance Images Orientation for the EADCâ€ADNI Manual Hippocampal Segmentation Protocol. Journal of Neuroimaging, 2014, 24, 509-514.	1.0	23
633	Role of Î²-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. JAMA Neurology, 2015, 72, 1475.	4.5	23
634	Statins and Brain Health: Alzheimerâ€™s Disease and Cerebrovascular Disease Biomarkers in Older Adults. Journal of Alzheimer's Disease, 2018, 65, 1345-1352.	1.2	23
635	â€œAlzheimer's diseaseâ€•is neither â€œAlzheimer's clinical syndromeâ€•nor â€œdementiaâ€• Alzheimer's and Dementia, 2019, 15, 153-157.	0.4	23
636	Brain imaging measurements of fibrillar amyloidâ€Î² burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE Îµ4 allele. Alzheimer's and Dementia, 2020, 16, 598-609.	0.4	23
637	Staging tau pathology with tau PET in Alzheimerâ€™s disease: a longitudinal study. Translational Psychiatry, 2021, 11, 483.	2.4	23
638	The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNIâ€3 updates and global perspectives. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12226.	1.8	23
639	Ventricular Enlargement and its Clinical Correlates in the Imaging Cohort From the ADCS MCI Donepezil/Vitamin E Study. Alzheimer Disease and Associated Disorders, 2013, 27, 174-181.	0.6	22
640	TDP-43 in Alzheimerâ€™s disease is not associated with clinical FTLD or Parkinsonism. Journal of Neurology, 2014, 261, 1344-1348.	1.8	22
641	Empowering imaging biomarkers of Alzheimer's disease. Neurobiology of Aging, 2015, 36, S69-S80.	1.5	22
642	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. Neurology, 2016, 87, 691-698.	1.5	22
643	Tracking the development of agrammatic aphasia: A tensor-based morphometry study. Cortex, 2017, 90, 138-148.	1.1	22
644	[ICâ€Pâ€122]: THE MAYO CLINIC ADULT LIFE SPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFE SPAN. Alzheimer's and Dementia, 2017, 13, P93.	0.4	22
645	Mediterranean Diet, Its Components, and Amyloid Imaging Biomarkers. Journal of Alzheimer's Disease, 2018, 64, 281-290.	1.2	22
646	Rates of lobar atrophy in asymptomatic MAPT mutation carriers. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 338-346.	1.8	22
647	Association of Longitudinal Î²-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. JAMA Network Open, 2019, 2, e1916439.	2.8	22
648	Neuroprotective effect of Coenzyme Q10 on ischemic hemisphere in aged mice with mutations in the amyloid precursor protein. Neurobiology of Aging, 2007, 28, 877-882.	1.5	21

#	Article	IF	Citations
649	Magnetic Resonance Imaging of Amyloid Plaques in Transgenic Mouse Models of Alzheimers Disease. Current Medical Imaging, 2011, 7, 3-7.	0.4	21
650	Neuroimaging in Dementia. Neurologic Clinics, 2007, 25, 843-857.	0.8	20
651	Neuroanatomical correlates of the progressive supranuclear palsy corticobasal syndrome hybrid. European Journal of Neurology, 2012, 19, 1440-1446.	1.7	20
652	Effects of changing from non-accelerated to accelerated MRI for follow-up in brain atrophy measurement. NeuroImage, 2015, 107, 46-53.	2.1	20
653	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. Neurobiology of Aging, 2016, 46, 32-42.	1.5	20
654	Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimerâ€™s disease. BMC Medical Genomics, 2016, 9, 30.	0.7	20
655	The Association of Mid- and Late-Life Systemic Inflammation with Brain Amyloid Deposition: The ARIC-PET Study. Journal of Alzheimer's Disease, 2018, 66, 1041-1052.	1.2	20
656	Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging. Alzheimer's and Dementia, 2020, 16, 1013-1022.	0.4	20
657	Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. Alzheimer's and Dementia, 2022, 18, 602-611.	0.4	20
658	Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiology. Brain, 2022, 145, 3594-3607.	3.7	20
659	Superficial temporal-middle cerebral artery bypass: clinical pre- and postoperative angiographic correlation. Journal of Neurosurgery, 1988, 69, 46-51.	0.9	19
660	How do spatial and angular resolution affect brain connectivity maps from diffusion MRI?. , 2012, , 1-6.		19
661	Imaging measures predict progression in progressive supranuclear palsy. Movement Disorders, 2012, 27, 1801-1804.	2.2	19
662	Mapping creatinine- and cystatin C-related white matter brain deficits in the elderly. Neurobiology of Aging, 2013, 34, 1221-1230.	1.5	19
663	Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type. Journal of Alzheimer's Disease, 2015, 45, 1109-1117.	1.2	19
664	Influence of preeclampsia and late-life hypertension on MRI measures of cortical atrophy. Journal of Hypertension, 2017, 35, 2479-2485.	0.3	19
665	Elevated medial temporal lobe and pervasive brain tauâ€PET signal in normal participants. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 210-216.	1.2	19
666	Multimodal neuroimaging relationships in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2019, 66, 56-61.	1.1	19

#	Article	IF	Citations
667	Cerebrospinal fluid dynamics disorders. Neurology, 2019, 93, e2237-e2246.	1.5	19
668	Linear vs volume measures of ventricle size. Neurology, 2020, 94, e549-e556.	1.5	19
669	Tauâ€Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. Annals of Neurology, 2021, 90, 751-762.	2.8	19
670	Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume. GeroScience, 2022, 44, 1807-1823.	2.1	19
671	Interscan registration using navigator echoes. Magnetic Resonance in Medicine, 2004, 52, 1448-1452.	1.9	18
672	Small world network measures predict white matter degeneration in patients with early-stage mild cognitive impairment. , 2012, , 1405-1408.		18
673	Effects of MRI scan acceleration on brain volume measurement consistency. Journal of Magnetic Resonance Imaging, 2012, 36, 1234-1240.	1.9	18
674	Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2016, 28, 29-35.	1.1	18
675	¹ H-MRS metabolites and rate of Î²-amyloid accumulation on serial PET in clinically normal adults. Neurology, 2017, 89, 1391-1399.	1.5	18
676	Efficacy and mechanisms of combined aerobic exercise and cognitive training in mild cognitive impairment: study protocol of the ACT trial. Trials, 2018, 19, 700.	0.7	18
677	Investigation of white matter PiB uptake as a marker of white matter integrity. Annals of Clinical and Translational Neurology, 2019, 6, 678-688.	1.7	18
678	Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults. Neurology, 2020, 94, e1571-e1579.	1.5	18
679	Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimerâ€™s pathophysiology. Acta Neuropathologica Communications, 2021, 9, 48.	2.4	18
680	Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. Alzheimer's and Dementia, 2021, 17, 801-812.	0.4	18
681	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. Brain Connectivity, 2021, 11, 239-249.	0.8	18
682	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. Neurobiology of Aging, 2021, 105, 252-261.	1.5	18
683	Algebraic Connectivity of Brain Networks Shows Patterns of Segregation Leading to Reduced Network Robustness in Alzheimerâ€™s Disease. Mathematics and Visualization, 2014, 2014, 55-64.	0.4	18
684	Sex Differences in the Association Between Midlife Cardiovascular Conditions or Risk Factors With Midlife Cognitive Decline. Neurology, 2022, 98, .	1.5	18

#	Article	IF	Citations
685	Functional Inferences Vary with the Method of Analysis in fMRI. NeuroImage, 2001, 14, 1122-1127.	2.1	17
686	Characterization of a Family With c9FTD/ALS Associated With the GGGGCC Repeat Expansion in C9ORF72. Archives of Neurology, 2012, 69, 1164-9.	4.9	17
687	Manual segmentation qualification platform for the EADCâ€ADNI harmonized protocol for hippocampal segmentation project. Alzheimer's and Dementia, 2015, 11, 161-174.	0.4	17
688	Spectral graph theory and graph energy metrics show evidence for the alzheimer's disease disconnection syndrome in APOE-4 risk gene carriers. , 2015, 2015, 458-461.		17
689	Imaging markers of cerebrovascular pathologies: Pathophysiology, clinical presentation, and risk factors. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 5-14.	1.2	17
690	Regional T₁ relaxation time constants in Ex vivo human brain: Longitudinal effects of formalin exposure. Magnetic Resonance in Medicine, 2017, 77, 774-778.	1.9	17
691	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102491.	1.4	17
692	18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. Brain Communications, 2020, 2, fcaa040.	1.5	17
693	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. Annals of Neurology, 2020, 87, 556-567.	2.8	17
694	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 707-721.	1.7	17
695	Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. Alzheimer's and Dementia, 2022, 18, 1370-1382.	0.4	17
696	Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging. Alzheimer's and Dementia, 2023, 19, 4498-4506.	0.4	17
697	Coronary Artery Bypass Graftingâ€Associated Ischemic Stroke; A Clinical and Neuroradiological Study. Journal of Neuroimaging, 1996, 6, 20-22.	1.0	16
698	Late-onset frontotemporal dementia associated with progressive supranuclear palsy/argyrophilic grain disease/Alzheimerâ€™s disease pathology. Neurocase, 2005, 11, 204-211.	0.2	16
699	Effects of Baseline CSF Î±-Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e85443.	1.1	16
700	Cortical Thickness and Anxiety Symptoms Among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. Journal of Neuropsychiatry and Clinical Neurosciences, 2017, 29, 60-66.	0.9	16
701	The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 877-883.	1.7	16
702	Diagnostic accuracy of the Cogstate Brief Battery for prevalent MCI and prodromal AD (MCI) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 Tc	0.4	16

#	Article	IF	Citations
703	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. Neurology, 2021, 96, e1632-e1645.	1.5	16
704	Autocorrection of Three-Dimensional Time-of-Flight MR Angiography of the Circle of Willis. American Journal of Roentgenology, 2001, 176, 513-518.	1.0	15
705	The GGGGCC Repeat Expansion inC9ORF72in a Case with Discordant Clinical and FDG-PET Findings: PET Trumps Syndrome. Neurocase, 2014, 20, 110-120.	0.2	15
706	Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. Neurology, 2017, 89, 2039-2048.	1.5	15
707	Cortical Thickness and Depressive Symptoms in Cognitively Normal Individuals: The Mayo Clinic Study ofÂAging. Journal of Alzheimer's Disease, 2017, 58, 1273-1281.	1.2	15
708	Association Between Microinfarcts and Blood Pressure Trajectories. JAMA Neurology, 2018, 75, 212.	4.5	15
709	Neuroanatomical correlates of phonologic errors in logopenic progressive aphasia. Brain and Language, 2020, 204, 104773.	0.8	15
710	Comparing amyloid-Î² plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. Acta Neuropathologica, 2021, 142, 689-706.	3.9	15
711	Relationships between Î²-amyloid and tau in an elderly population: An accelerated failure time model. NeuroImage, 2021, 242, 118440.	2.1	15
712	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. Brain Communications, 2022, 4, fcac013.	1.5	15
713	Microbleeds in the logopenic variant of primary progressive aphasia. Alzheimer's and Dementia, 2014, 10, 62-66.	0.4	14
714	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 669-677.	1.2	14
715	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. Neurobiology of Aging, 2019, 83, 54-62.	1.5	14
716	Brain atrophy in primary ageâ€related tauopathy is linked to transactive response DNAâ€binding protein of 43 kDa. Alzheimer's and Dementia, 2019, 15, 799-806.	0.4	14
717	Preclinical Alzheimer's disease: a valid concept. Lancet Neurology, The, 2020, 19, 31.	4.9	14
718	Exposure to surgery with general anaesthesia during adult life is not associated with increased brain amyloid deposition in older adults. British Journal of Anaesthesia, 2020, 124, 594-602.	1.5	14
719	CSF biomarkers in Olmsted County. Neurology, 2020, 95, e256-e267.	1.5	14
720	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. Neurobiology of Aging, 2020, 88, 42-50.	1.5	14

#	Article	IF	Citations
721	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimerâ€™s Disease Neuropathological Changes. Journal of Alzheimer's Disease, 2020, 73, 1511-1523.	1.2	14
722	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. Acta Neuropathologica Communications, 2022, 10, 16.	2.4	14
723	Visit-to-Visit Blood Pressure Variability and Longitudinal Tau Accumulation in Older Adults. Hypertension, 2022, 79, 629-637.	1.3	14
724	A longitudinal investigation of AÎ², anxiety, depression, and mild cognitive impairment. Alzheimer's and Dementia, 2022, 18, 1824-1831.	0.4	14
725	Magnetic-resonance-imaging-based volume studies in patients with bitemporal epileptiform abnormalities. Journal of Epilepsy, 1992, 5, 210-213.	0.4	13
726	Distinctive MRI findings in pallidopontonigral degeneration (PPND). Neurology, 2007, 68, 620-621.	1.5	13
727	Diffusion tensor imaging in seven minutes: Determining trade-offs between spatial and directional resolution. , 2010, , .		13
728	Exposure to surgery under general anaesthesia and brain magnetic resonance imaging changes in older adults. British Journal of Anaesthesia, 2019, 123, 808-817.	1.5	13
729	Î²-Amyloid PET and ¹²³ I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. Neurology, 2021, 96, .	1.5	13
730	White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline. Brain Communications, 2021, 3, fcab076.	1.5	13
731	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. Journal of Neuroimaging, 2021, 31, 1020-1027.	1.0	13
732	Mapping Dynamic Changes in Ventricular Volume onto Baseline Cortical Surfaces in Normal Aging, MCI, and Alzheimerâ€™s Disease. Lecture Notes in Computer Science, 2013, 8159, 84-94.	1.0	13
733	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. Neurology, 2020, 95, e3190-e3202.	1.5	13
734	Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy. NeuroImage: Clinical, 2021, 32, 102850.	1.4	13
735	Traumatic brain injury and postâ€traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers. Alzheimer's and Dementia, 2023, 19, 884-895.	0.4	13
736	Ultrasonic features of two cases of spinal cord hemangioblastoma. World Neurosurgery, 1986, 26, 453-456.	1.3	12
737	Risk factor profile for chronic kidney disease is similar to risk factor profile for small artery disease. Journal of Hypertension, 2011, 29, 1796-1801.	0.3	12
738	Altered Functional MR Imaging Language Activation in Elderly Individuals with Cerebral Leukoaraiosis. Radiology, 2012, 265, 222-232.	3.6	12

#	Article	IF	Citations
739	Seemingly unrelated regression empowers detection of network failure in dementia. Neurobiology of Aging, 2015, 36, S103-S112.	1.5	12
740	Associations of Brain Structure With Adiposity and Changes in Adiposity in a Middle-Aged and Older Biracial Population. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, glw239.	1.7	12
741	Neural correlates of domain-specific cognitive decline. Neurology, 2019, 92, e1051-e1063.	1.5	12
742	Variants inPPP2R2BandIGF2BP3are associated with higher tau deposition. Brain Communications, 2020, 2, fcaa159.	1.5	12
743	Aortic Stiffness and White Matter Microstructural Integrity Assessed by Diffusion Tensor Imaging: The ARICâ€NCS. Journal of the American Heart Association, 2020, 9, e014868.	1.6	12
744	The transformative potential of plasma phosphorylated tau. Lancet Neurology, The, 2020, 19, 373-374.	4.9	12
745	Prospective Analysis of Leisure-Time Physical Activity in Midlife and Beyond and Brain Damage on MRI in Older Adults. Neurology, 2021, 96, e964-e974.	1.5	12
746	Imaging-based indices of Neuropathology and gait speed decline in older adults: the atherosclerosis risk in communities study. Brain Imaging and Behavior, 2021, 15, 2387-2396.	1.1	12
747	Diffusion tensor imaging analysis in three progressive supranuclear palsy variants. Journal of Neurology, 2021, 268, 3409-3420.	1.8	12
748	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. Brain Communications, 2021, 3, fcab182.	1.5	12
749	Modeling autosomal dominant Alzheimer's disease with machine learning. Alzheimer's and Dementia, 2021, 17, 1005-1016.	0.4	12
750	The association of motoric cognitive risk with incident dementia and neuroimaging characteristics: The Atherosclerosis Risk in Communities Study. Alzheimer's and Dementia, 2022, 18, 434-444.	0.4	12
751	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. Brain Communications, 2022, 4, fcac017.	1.5	12
752	Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease. Neurology, 2022, 98, .	1.5	12
753	Primary lateral sclerosis as progressive supranuclear palsy: Diagnosis by diffusion tensor imaging. Movement Disorders, 2012, 27, 903-906.	2.2	11
754	Clinicopathological and ¹²³Iâ€<scp>FP</scp>â€<scp>CIT SPECT</scp> correlations in patients with dementia. Annals of Clinical and Translational Neurology, 2018, 5, 376-381.	1.7	11
755	Reply: LATE to the PART-y. Brain, 2019, 142, e48-e48.	3.7	11
756	Dementia is not synonymous with Alzheimerâ€™s disease. Science Translational Medicine, 2019, 11, .	5.8	11

#	Article	IF	Citations
757	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimerâ€™s disease. Brain Communications, 2020, 2, fcaa102.	1.5	11
758	Neuronal insulin signaling and brain structure in nondemented older adults: the Atherosclerosis Risk in Communities Study. Neurobiology of Aging, 2021, 97, 65-72.	1.5	11
759	Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. Neurobiology of Aging, 2021, 108, 90-98.	1.5	11
760	Longitudinal deterioration of white-matter integrity: heterogeneity in the ageing population. Brain Communications, 2021, 3, fcaa238.	1.5	11
761	Predictive value of ATN biomarker profiles in estimating disease progression in Alzheimer's disease dementia. Alzheimer's and Dementia, 2021, 17, 1855-1867.	0.4	11
762	Tractography of supplementary motor area projections in progressive speech apraxia and aphasia. NeuroImage: Clinical, 2022, 34, 102999.	1.4	11
763	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimerâ€™s disease. Nature Communications, 2022, 13, 1495.	5.8	11
764	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. Movement Disorders, 2022, 37, 1256-1264.	2.2	11
765	An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-Îµ4 in female patients with Alzheimerâ€™s disease. Nature Aging, 2022, 2, 616-634.	5.3	11
766	Neuropathologic scales of cerebrovascular disease associated with diffusion changes on MRI. Acta Neuropathologica, 2022, 144, 1117-1125.	3.9	11
767	Does MRI scan acceleration affect power to track brain change?. Neurobiology of Aging, 2015, 36, S167-S177.	1.5	10
768	Sample size calculations for clinical trials targeting tauopathies: a new potential disease target. Journal of Neurology, 2015, 262, 2064-2072.	1.8	10
769	Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech. NeuroImage: Clinical, 2016, 11, 90-98.	1.4	10
770	Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia. Journal of the American Geriatrics Society, 2018, 66, 2274-2281.	1.3	10
771	Association of Atrial Fibrillation With White Matter Disease. Stroke, 2019, 50, 989-991.	1.0	10
772	The influence of Î²-amyloid on [¹⁸ F]AV-1451 in semantic variant of primary progressive aphasia. Neurology, 2019, 92, e710-e722.	1.5	10
773	Atrial Fibrillation, Brain Volumes, and Subclinical Cerebrovascular Disease (from the Atherosclerosis) Tj ETQq1 1 0.784314 rgBT /Overl 222-228.	0.7	10
774	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-Î² PET Signal. Neurology, 2021, 97, e1799-e1808.	1.5	10

#	Article	IF	Citations
775	Primary Progressive Aphasia. Psychosomatics, 1994, 35, 138-141.	2.5	9
776	Mapping hippocampal degeneration in 400 subjects with a novel automated segmentation approach. , 2008, , .		9
777	Boosting power to detect genetic associations in imaging using multi-locus, genome-wide scans and ridge regression. , 2011, , .		9
778	Steroid-responsive encephalopathy subsequently associated with Alzheimer's disease pathology: A case series. Neurocase, 2012, 18, 1-12.	0.2	9
779	Brain Atrophy on Magnetic Resonance Imaging as a Biomarker of Neurodegeneration. JAMA Neurology, 2016, 73, 1179.	4.5	9
780	Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. Journal of Neuro-Oncology, 2018, 136, 373-378.	1.4	9
781	Considerations for Performing Level-2 Centiloid Transformations for Amyloid PET SUVR values. Scientific Reports, 2018, 8, 7421.	1.6	9
782	The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. Journal of Alzheimer's Disease, 2018, 64, 149-169.	1.2	9
783	Association of Cortical and Subcortical Î²-Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 2021, 33, 64-71.	0.9	9
784	The Impact of Amyloid Burden and APOE on Rates of Cognitive Impairment in Late Life Depression. Journal of Alzheimer's Disease, 2021, 80, 991-1002.	1.2	9
785	Cerebral Microbleeds. Stroke, 2021, 52, 2347-2355.	1.0	9
786	Regional Age-Related Atrophy After Screening for Preclinical Alzheimer Disease. Neurobiology of Aging, 2021, 109, 43-51.	1.5	9
787	Mechanistic Effects of Aerobic Exercise in Alzheimer's Disease: Imaging Findings From the Pilot FIT-AD Trial. Frontiers in Aging Neuroscience, 2021, 13, 703691.	1.7	9
788	1H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults. Neurobiology of Aging, 2022, 112, 16-26.	1.5	9
789	Deep learning identifies brain structures that predict cognition and explain heterogeneity in cognitive aging. NeuroImage, 2022, 251, 119020.	2.1	9
790	New technical developments in magnetic resonance imaging of epilepsy. Magnetic Resonance Imaging, 1995, 13, 1095-1098.	1.0	8
791	Focal brain atrophy in gastric bypass patients with cognitive complaints. Journal of Clinical Neuroscience, 2011, 18, 1671-1676.	0.8	8
792	[ICâ€Pâ€137]: ADNIâ€3 MRI PROTOCOL. Alzheimer's and Dementia, 2017, 13, P104.	0.4	8

#	Article	IF	Citations
793	Practical algorithms for amyloid Î² probability in subjective or mild cognitive impairment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 710-720.	1.2	8
794	Elevated Plasma Ceramides Are Associated With Higher White Matter Hyperintensity Volumeâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2431-2436.	1.1	8
795	Amyloid PET and Changes in Clinical Management for Patients With Cognitive Impairment. JAMA - Journal of the American Medical Association, 2019, 321, 1258.	3.8	8
796	Phonological Errors in Posterior Cortical Atrophy. Dementia and Geriatric Cognitive Disorders, 2021, 50, 195-203.	0.7	8
797	Common Medications and Intracerebral Hemorrhage: The ARIC Study. Journal of the American Heart Association, 2021, 10, e014270.	1.6	8
798	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. Journal of Alzheimer's Disease, 2021, 81, 113-122.	1.2	8
799	Sex Difference in the Relation Between Marital Status and Dementia Risk in Two Population-Based Cohorts. Journal of Alzheimer's Disease, 2021, 83, 1269-1279.	1.2	8
800	Automatic Prediction of Conversion from Mild Cognitive Impairment to Probable Alzheimer's Disease using Structural Magnetic Resonance Imaging. AMIA ... Annual Symposium proceedings, 2010, 2010, 542-6.	0.2	8
801	A novel computer adaptive word list memory test optimized for remote assessment: Psychometric properties and associations with neurodegenerative biomarkers in older women without dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12299.	1.2	8
802	Glucose metabolism patterns: A potential index to characterize brain ageing and predict high conversion risk into cognitive impairment. GeroScience, 2022, 44, 2319-2336.	2.1	8
803	Causal structure discovery identifies risk factors and early brain markers related to evolution of white matter hyperintensities. NeuroImage: Clinical, 2022, 35, 103077.	1.4	8
804	Early childhood diagnosis of acoustic neuromas in presymptomatic individuals at risk for neurofibromatosis 2. American Journal of Medical Genetics Part A, 1991, 41, 325-329.	2.4	7
805	Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative Diseases. Therapeutic Innovation and Regulatory Science, 2013, 47, 632-638.	0.8	7
806	Massachusetts Alzheimer's Disease Research Center: Progress and challenges. Alzheimer's and Dementia, 2015, 11, 1241-1245.	0.4	7
807	Uptake of AV-1451 in meningiomas. Annals of Nuclear Medicine, 2017, 31, 736-743.	1.2	7
808	Creating three dimensional models of Alzheimerâ€™s disease. 3D Printing in Medicine, 2017, 3, 13.	1.7	7
809	Amyloid-Î² â€" a reflection of risk or a preclinical marker?. Nature Reviews Neurology, 2018, 14, 319-320.	4.9	7
810	Factors Associated With Meningioma Detected in a Population-Based Sample. Mayo Clinic Proceedings, 2019, 94, 254-261.	1.4	7

#	Article	IF	Citations
811	Plasma Metabolites Associated with Brain MRI Measures of Neurodegeneration in Older Adults in the Atherosclerosis Risk in Communitiesâ€"Neurocognitive Study (ARIC-NCS). International Journal of Molecular Sciences, 2019, 20, 1744.	1.8	7
812	Longitudinal association between phosphatidylcholines, neuroimaging measures of Alzheimer's disease pathophysiology, and cognition in the Mayo Clinic Study of Aging. Neurobiology of Aging, 2019, 79, 43-49.	1.5	7
813	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism and Related Disorders, 2019, 60, 138-145.	1.1	7
814	Longitudinal Amyloid-Î² PET in Atypical Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 74, 377-389.	1.2	7
815	Associations Between Plasma Ceramides and Cerebral Microbleeds or Lacunes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2785-2793.	1.1	7
816	Brain MRI after critical care admission: A longitudinal imaging study. Journal of Critical Care, 2021, 62, 117-123.	1.0	7
817	Brain White Matter Structure and Amyloid Deposition in Black and White Older Adults: The ARICâ€PET Study. Journal of the American Heart Association, 2021, 10, e022087.	1.6	7
818	A Comparison of Cross-Sectional and Longitudinal Methods of Defining Objective Subtle Cognitive Decline in Preclinical Alzheimerâ€™s Disease Based on Cogstate One Card Learning Accuracy Performance. Journal of Alzheimer's Disease, 2021, 83, 861-877.	1.2	7
819	Cerebrospinal Fluid Dynamics and Discordant Amyloid Biomarkers. Neurobiology of Aging, 2021, 110, 27-36.	1.5	7
820	Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a series of clinical cases. Journal of Neurology, 2022, 269, 4110-4128.	1.8	7
821	Dissection of the polygenic architecture of neuronal AÎ² production using a large sample of individual iPSC lines derived from Alzheimerâ€™s disease patients. Nature Aging, 2022, 2, 125-139.	5.3	7
822	Posterior cortical atrophy: Primary occipital variant. European Journal of Neurology, 2022, 29, 2138-2143.	1.7	7
823	APOE Îµ4 influences medial temporal atrophy and tau deposition in atypical Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 784-796.	0.4	7
824	Radiologic evaluation of extracranial to sylvian middle cerebral artery bypass. World Neurosurgery, 1986, 26, 321-329.	1.3	6
825	Acute depth electrode investigations in temporal lobe epilepsy: Correlation with magnetic-resonance-imaging-based volume studies and pathology. Journal of Epilepsy, 1992, 5, 49-54.	0.4	6
826	A single nucleotide polymorphism associated with reduced alcohol intake in the RASGRF2 gene predicts larger cortical volumes but faster longitudinal ventricular expansion in the elderly. Frontiers in Aging Neuroscience, 2013, 5, 93.	1.7	6
827	Spontaneous amyloid-related imaging abnormalities in a cognitively normal adult. Neurology, 2014, 83, 1771-1772.	1.5	6
828	Association of Carotid Intima-Media Thickness with Brain MRI Markers in the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106388.	0.7	6

#	Article	IF	Citations
829	Artificial Intelligenceâ€"Enabled Electrocardiogram for Atrial Fibrillation Identifies Cognitive Decline Risk and Cerebral Infarcts. Mayo Clinic Proceedings, 2022, 97, 871-880.	1.4	6
830	Face recognition from research brain PET: An unexpected PET problem. NeuroImage, 2022, 258, 119357.	2.1	6
831	Sleepiness in Cognitively Unimpaired Older Adults Is Associated With CSF Biomarkers of Inflammation and Axonal Integrity. Frontiers in Aging Neuroscience, 0, 14, .	1.7	6
832	Functional brain imaging with a standard 1.5-T magnetic resonance imaging system. Academic Radiology, 1995, 2, 916-923.	1.3	5
833	[FTS3â€"02â€"01]: 2017 NIAâ€AA RESEARCH FRAMEWORK TO INVESTIGATE THE ALZHEIMER's DISEASE CONTINUUM. Alzheimer's and Dementia, 2017, 13, P890.	0.4	5
834	Frequency of Acute and Subacute Infarcts in a Population-Based Study. Mayo Clinic Proceedings, 2018, 93, 300-306.	1.4	5
835	Cardiorespiratory Fitness and Brain Volumes. Mayo Clinic Proceedings, 2020, 95, 6-8.	1.4	5
836	Longitudinal flortaucipir ([18F]AV-1451) PET imaging in primary progressive apraxia of speech. Cortex, 2020, 124, 33-43.	1.1	5
837	Association of mid-life serum lipid levels with late-life brain volumes: The atherosclerosis risk in communities neurocognitive study (ARIC NCS). NeuroImage, 2020, 223, 117324.	2.1	5
838	CSF dynamics disorders: Association of brain MRI and nuclear medicine cisternogram findings. NeuroImage: Clinical, 2020, 28, 102481.	1.4	5
839	Study of Symptomatic vs. Silent Brain Infarctions on MRI in Elderly Subjects. Frontiers in Neurology, 2021, 12, 615024.	1.1	5
840	Sleep quality and cortical amyloid-Î² deposition in postmenopausal women of the Kronos early estrogen prevention study. NeuroReport, 2021, 32, 326-331.	0.6	5
841	The prospective association between periodontal disease and brain imaging outcomes: The Atherosclerosis Risk in Communities study. Journal of Clinical Periodontology, 2022, 49, 322-334.	2.3	5
842	Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies. Brain Communications, 2022, 4, .	1.5	5
843	Mayo normative studies: A conditional normative model for longitudinal change on the Auditory Verbal Learning Test and preliminary validation in preclinical Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	1.2	5
844	Dual-Echo Interleaved Echo-Planar Imaging of the Brain. Magnetic Resonance in Medicine, 1995, 33, 264-270.	1.9	4
845	Effects of a Stereotactic Headframe Assembly on Proton Magnetic Resonance Spectroscopy. Stereotactic and Functional Neurosurgery, 1998, 71, 190-202.	0.8	4
846	Mapping ventricular expansion and its clinical correlates in Alzheimer's disease and mild cognitive impairment using multi-atlas fluid image alignment. , 2009, , .		4

#	Article	IF	Citations
847	MRI Substudy Participation in Alzheimer Disease (AD) Clinical Trials. Alzheimer Disease and Associated Disorders, 2009, 23, 333-336.	0.6	4
848	Alzheimerâ€™s Disease Classification with Novel Microstructural Metrics from Diffusion-Weighted MRI. Mathematics and Visualization, 2016, , 41-54.	0.4	4
849	Amyloid- and tau-PET imaging in a familial prion kindred. Neurology: Genetics, 2018, 4, e290.	0.9	4
850	Non-right handed primary progressive apraxia of speech. Journal of the Neurological Sciences, 2018, 390, 246-254.	0.3	4
851	Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12197.	1.2	4
852	Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphereâ€"Predominant Logopenic Progressive Aphasia. Neurology, 2021, 97, e523-e534.	1.5	4
853	Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy. Movement Disorders, 2021, 36, 2669-2675.	2.2	4
854	Bivariate Genome-Wide Association Study of Genetically Correlated Neuroimaging Phenotypes from DTI and MRI through a Seemingly Unrelated Regression Model. Lecture Notes in Computer Science, 2013, , 189-201.	1.0	4
855	Ranking diffusion tensor measures of brain aging and Alzheimerâ€™s disease. , 2018, , .		4
856	Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. Journal of Alzheimer's Disease, 2022, 87, 1537-1547.	1.2	4
857	CSF phosphorylated tau as an indicator of subsequent tau accumulation. Neurobiology of Aging, 2022, 117, 189-200.	1.5	4
858	Physical Frailty and Brain White Matter Abnormalities: The ARIC Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 0, , .	1.7	4
859	Relationships of Cerebral Perfusion With Gait Speed Across Systolic Blood Pressure Levels and Age: A Cohort Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2023, 78, 514-520.	1.7	4
860	Food (and vitamins) for thought. Neurology, 2002, 58, 1449-1450.	1.5	3
861	Understanding scanner upgrade effects on brain integrity & connectivity measures. , 2014, , .		3
862	P4-137: THE TRANSITIONAL ASSOCIATION BETWEEN BETA-AMYLOID PATHOLOGY AND REGIONAL BRAIN ATROPHY. , 2014, 10, P837-P838.		3
863	An MRIâ€Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease. Journal of Neuroimaging, 2016, 26, 264-268.	1.0	3
864	Alzheimer's disease biomarker development: a call to funding bodies. Neurobiology of Aging, 2017, 52, 117-118.	1.5	3

#	Article	IF	Citations
865	Multi-Shell Diffusion MRI Measures of Brain Aging: A Preliminary Comparison From ADNI3. , 2019, , .		3
866	Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia. Neurobiology of Aging, 2020, 92, 135-140.	1.5	3
867	Alzheimer Disease, Biomarkers, and Clinical Symptomsâ€"Quo Vadis?â€"Reply. JAMA Neurology, 2020, 77, 394.	4.5	3
868	Brain amyloid, cortical thickness, and changes in activities of daily living. Annals of Clinical and Translational Neurology, 2020, 7, 474-485.	1.7	3
869	CSF dynamics as a predictor of cognitive progression. NeuroImage, 2021, 232, 117899.	2.1	3
870	Lipidomic Network of Mild Cognitive Impairment from the Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2021, 81, 533-543.	1.2	3
871	Chronic Kidney Disease Associated with Worsening White Matter Disease and Ventricular Enlargement. Journal of Alzheimer's Disease, 2021, 83, 1729-1740.	1.2	3
872	Disrupted Brain Connectivity in Alzheimerâ€™s Disease: Effects of Network Thresholding. Mathematics and Visualization, 2014, , 199-208.	0.4	3
873	Neuroimaging in Alzheimer Disease. , 2006, , 142-159.		3
874	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. NeuroImage: Clinical, 2022, 34, 102954.	1.4	3
875	Association of Performance on the Financial Capacity Instrumentâ€"Short Form With Brain Amyloid Load and Cortical Thickness in Older Adults. Neurology: Clinical Practice, 2022, 12, 113-124.	0.8	3
876	Leftâ€"Right Intensity Asymmetries Vary Depending on Scanner Model for FLAIR and T 1 Weighted MRI Images. Journal of Magnetic Resonance Imaging, 2022, , .	1.9	3
877	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimerâ€™s disease. Acta Neuropathologica, 2022, 143, 571-583.	3.9	3
878	Neuroimaging in Dementia. PET Clinics, 2007, 2, 15-24.	1.5	2
879	Ventricular maps in 804 subjects correlate with cognitive decline, CSF pathology, and imminent Alzheimer's disease. , 2010, 2010, 241-244.		2
880	Principal components regression: Multivariate, gene-based tests in imaging genomics. , 2011, , .		2
881	O3-03-01: Update on hypothetical model of Alzheimer's disease biomarkers. , 2013, 9, P521-P522.		2
882	Evaluation of diffusion imaging protocols for the Alzheimer's disease Neuroimaging Initiative. , 2014, , .		2

#	Article	IF	Citations
883	ICIâ€02â€01: Alzheimer's Disease Imaging Biomarkers and Aging. Alzheimer's and Dementia, 2016, 12, P12.	0.4	2
884	Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome. Neurology: Genetics, 2017, 3, e201.	0.9	2
885	A Joint Model for Predicting Structural and Functional Brain Health in Elderly Individuals. , 2019, , .		2
886	Progressive hippocampal atrophy in chronic intractable temporal lobe epilepsy. , 1999, 45, 526.		2
887	Power Estimates for Voxel-Based Genetic Association Studies Using Diffusion Imaging. Mathematics and Visualization, 2014, , 229-238.	0.4	2
888	Changes in Ventricular and Cortical Volumes following Shunt Placement in Patients with Idiopathic Normal Pressure Hydrocephalus. American Journal of Neuroradiology, 2021, , .	1.2	2
889	Biomarker clustering in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 274-284.	0.4	2
890	Disparities in dementia and AD biomarkers in the ARIC study: The important contribution of social determinants of health. Alzheimer's and Dementia, 2021, 17, .	0.4	2
891	Brain Imaging Features Associated with 20-Year Cognitive Decline in a Community-Based Multiethnic Cohort without Dementia. Neuroepidemiology, 2022, 56, 183-191.	1.1	2
892	Polygenic Scores of Alzheimerâ€™s Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden. Journal of Alzheimer's Disease, 2022, 88, 1615-1625.	1.2	2
893	Radiolabeled polyvinyl alcohol particles: A potential agent to monitor embolization procedures. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1986, 13, 235-243.	0.3	1
894	Real-time auto-shimming for FMRI. NeuroImage, 2001, 13, 52.	2.1	1
895	<title>Spherical navigator echoes for full 3D rigid body motion measurement in MRI</title>. , 2001, , .		1
896	Reply: Multiple imputation models should incorporate the outcome in the model of interest. Brain, 2011, 134, e190-e190.	3.7	1
897	Ordering of Alzheimer Disease Biomarkersâ€"Reply. Archives of Neurology, 2012, 69, 414.	4.9	1
898	O2â€06â€01: Disrupted functional connectivity in autosomal dominant Alzheimer's disease: Preliminary findings from the DIAN study. Alzheimer's and Dementia, 2012, 8, P244.	0.4	1
899	MRS in Early and Presymptomatic Carriers of a Novel Octapeptide Repeat Insertion in the Prion Protein Gene. Journal of Neuroimaging, 2013, 23, 409-413.	1.0	1
900	Manual segmentation certification platform. , 2013, , .		1

#	Article	IF	Citations
901	Diffusion tensor distribution function metrics boost power to detect deficits in Alzheimer's disease. , 2016, , .		1
902	[P3â€“356]: VENTRICULOMEGALY IS A BIOMARKER OF GAIT AND COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P1092.	0.4	1
903	[P4â€“242]: ADNIâ€3 MRI ACQUISITIONS. Alzheimer's and Dementia, 2017, 13, P1368.	0.4	1
904	Diffusion Specific Segmentation: Skull Stripping with Diffusion MRI Data Alone. Mathematics and Visualization, 2018, , 67-80.	0.4	1
905	P2â€334: THE INFLUENCE OF BETAâ€AMYLOID ON THE PROGRESSION OF PROGRESSIVE APRAXIA OF SPEECH. Alzheimer's and Dementia, 2018, 14, P810.	0.4	1
906	FTS4â€01â€01: OVERVIEW OF NIAâ€AA RESEARCH FRAMEWORK. Alzheimer's and Dementia, 2018, 14, P1398.	0.4	1
907	Incidence of Convexal Subarachnoid Hemorrhage in the Elderly: The Mayo Clinic Study of Aging. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 104451.	0.7	1
908	Predicting future rates of tau accumulation on PET. Alzheimer's and Dementia, 2020, 16, e044594.	0.4	1
909	Apolipoprotein E É›4â€“related effects on cognition are limited to the Alzheimerâ€™s disease spectrum. GeroScience, 2022, 44, 195-209.	2.1	1
910	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. , 2011, 7, 263.		1
911	Associations between cerebrospinal fluid total phosphatidylcholines, neurodegeneration, cognitive decline, and risk of mild cognitive impairment in the Mayo Clinic Study of Aging. Neurobiology of Aging, 2020, 93, 52-54.	1.5	1
912	Epidemiologic study of risk factors for meningioma in the Mayo Clinic Study of Aging.. Journal of Clinical Oncology, 2017, 35, 2067-2067.	0.8	1
913	Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual. Journal of Alzheimer's Disease, 2021, , 1-6.	1.2	1
914	White matter changes in empirically derived incident MCI subtypes in the Mayo Clinic Study of Aging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12269.	1.2	1
915	P3-339 Longitudinal characterization of two siblings with frontotemporal dementia associated with the S305N tau mutation. Neurobiology of Aging, 2004, 25, S451-S452.	1.5	0
916	P3-078 Brain atrophy rate measures correlate with subsequent clinical course in normal and impaired elderly subjects. Neurobiology of Aging, 2004, 25, S375.	1.5	0
917	Diurnal blood pressure rhythm predicts ischemic brain damage. American Journal of Hypertension, 2005, 18, A244-A244.	1.0	0
918	Magnetic Resonance Imaging Research in Aging and Dementia at the Mayo Clinic. Alzheimer Disease and Associated Disorders, 2008, 22, 204-208.	0.6	0

#	Article	IF	Citations
919	Iron imaging in neurodegenerative disorders. , 0, , 642-652.		0
920	Proton MR spectroscopy in aging and dementia. , 0, , 618-629.		0
921	Phantom-based MRI corrections and power to track brain change. , 2012, , .		0
922	MRI- and PET-Based Imaging Markers for the Diagnosis of Alzheimerâ€™s Disease. Advances in Biological Psychiatry, 2012, , 80-114.	0.2	0
923	O3-10-03: SEX AND APOE EFFECTS ON MEMORY PERFORMANCE, NEURODEGENERATION, AND B-AMYLOID ACROSS THE ADULT LIFESPAN. , 2014, 10, P228-P229.		0
924	Neuroimaging in Dementias. , 2015, , 107-118.		0
925	P2â€248: Neuropsychological and MRI Findings in MAPT Mutation Carriers in the Evolution from the Asymptomatic to Symptomatic State. Alzheimer's and Dementia, 2016, 12, P720.	0.4	0
926	[ICâ€Pâ€021]: INVESTIGATION OF PITTSBURGH COMPOUNDâ€B BINDING IN WHITE MATTER HYPERINTENSITIES. Alzheimer's and Dementia, 2017, 13, P23.	0.4	0
927	[ICâ€Pâ€057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P47.	0.4	0
928	[P3â€“249]: LOW HEMOGLOBIN LEVEL IS ASSOCIATED WITH BRAIN MICROSTRUCTURAL INTEGRITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Alzheimer's and Dementia, 2017, 13, P1037.	0.4	0
929	[P2â€“372]: UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P768.	0.4	0
930	[P1â€“393]: PATTERN OF HYPOPERFUSION ON ASL OVERLAPS WITH HYPOMETABOLISM ON FDGâ€PET IN DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2017, 13, P418.	0.4	0
931	[P3â€“242]: PLASMA TOTAL TAU, COGNITIVE DECLINE, AND RISK OF MILD COGNITIVE IMPAIRMENT IN THE MAYO CLINIC STUDY ON AGING. Alzheimer's and Dementia, 2017, 13, P1032.	0.4	0
932	[P3â€“343]: INVESTIGATION OF PITTSBURGH COMPOUNDâ€B BINDING IN WHITE MATTER HYPERINTENSITIES. Alzheimer's and Dementia, 2017, 13, P1085.	0.4	0
933	[P3â€“021]: THE ROLE OF CARDIOVASCULAR HEALTH IN MODERATING THE EFFECTS OF POSTMENOPAUSAL HORMONE THERAPY ON NEUROIMAGING OUTCOMES. Alzheimer's and Dementia, 2017, 13, P937.	0.4	0
934	[ICâ€Pâ€072]: AUTOMATED MEASUREMENT OF SULCAL CSF SPACES TO DETECT IMAGING PHENOTYPES OF DISPROPORTIONATELY ENLARGED SUBARACHNOID HYDROCEPHALUS. Alzheimer's and Dementia, 2017, 13, P59.	0.4	0
935	[ICâ€Pâ€150]: CHARACTERISING PRESYMPTOMATIC ATROPHY PATTERNS THROUGH MULTIVARIATE MACHINE LEARNING. Alzheimer's and Dementia, 2017, 13, P113.	0.4	0
936	[ICâ€Pâ€166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P125.	0.4	0

#	Article	IF	Citations
937	[ICâ€Pâ€204]: SUBJECTâ€LEVEL ASSESSMENT OF REGIONAL CORRELATIONS BETWEEN TAUâ€PET, AMYLOIDâ€PET, MRI AND FDGâ€PET ACROSS THE CLINICAL SPECTRUM OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P149.	0.4	0
938	[P1â€“380]: AUTOMATED MEASURMENT OF SULCAL CSF SPACES TO DETECT IMAGING PHENOTYPES OF DISPROPORTIONATELY ENLARGED SUBARACHNOID HYDROCEPHALUS. Alzheimer's and Dementia, 2017, 13, P410.	0.4	0
939	[P1â€“384]: A NOVEL 18Fâ€FDG PETâ€CT PATTERN IN IDIOPATHIC NORMAL PRESSURE HYDROCEPHALUS. Alzheimer's and Dementia, 2017, 13, P413.	0.4	0
940	[P1â€“457]: LONGITUDINAL ASSOCIATIONS BETWEEN CEREBRAL AMYLOID DEPOSITION, CORTICAL THICKNESS, AND GAIT IN THE MAYO CLINIC STUDY OF AGING. Alzheimer's and Dementia, 2017, 13, P461.	0.4	0
941	[O1â€“02â€“03]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P186.	0.4	0
942	[F3â€“01â€“01]: OPPORTUNITIES AND CHALLENGES FOR IMPLEMENTING ALZHEIMERS BIOMARKERS IN RESEARCH STUDIES. Alzheimer's and Dementia, 2017, 13, P878.	0.4	0
943	[O1â€“02â€“04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P186.	0.4	0
944	ICâ€Pâ€160: STRESS: BETTER COPING ASSOCIATED WITH LOWER TAU IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P128.	0.4	0
945	tau-PET signal elevation in selective basal forebrain nuclei is associated with excessive daytime sleepiness in cognitively unimpaired middle aged and older adults. Sleep Medicine, 2019, 64, S56-S57.	0.8	0
946	Neuroimaging in dementias. , 2020, , 187-197.		0
947	Abstract P708: Artificial Intelligence Enabled-Electrocardiography for the Detection of Cerebral Infarcts in Patients With Atrial Fibrillation. Stroke, 2021, 52, .	1.0	0
948	Abstract P49: Pattern of Cerebral Microbleeds and Cerebral Amyloid: The ARIC-PET Study. Stroke, 2021, 52, .	1.0	0
949	Regional Brain Stiffness Analysis of Dementia with Lewy Bodies. Journal of Magnetic Resonance Imaging, 2022, 55, 1907-1909.	1.9	0
950	Predicting Progression of Alzheimerâ€™s Disease With Magnetic Resonance. , 2005, , 95-105.		0
951	10 Neuroimaging in Alzheimer Disease. , 2011, , 167-182.		0
952	Using Multiple Diffusion MRI Measures to Predict Alzheimerâ€™s Disease with a TV-L1 Prior. Mathematics and Visualization, 2017, , 157-166.	0.4	0
953	Quantitative magnetic resonance techniques as surrogate markers of Alzheimerâ€™s disease. Neurotherapeutics, 2004, 1, 196-205.	2.1	0
954	Abstract 13193: Association of Abnormal P-wave Indices With Brain MRI Infarcts: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). Circulation, 2020, 142, .	1.6	0

#	Article	IF	Citations
955	Association of Indication for Hospitalization With Subsequent Amyloid Positron Emission Tomography and Magnetic Resonance Imaging Biomarkers. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2023, 78, 304-313.	1.7	0
956	Response to â€œOn the reproducibility of quantitative susceptibility mapping and its potential as a clinical biomarker: A comment on Cogswell etÂal. 2021â€• NeuroImage, 2022, 251, 118992.	2.1	0
957	Associations of Central Auditory Processing With Brain Volumes. Innovation in Aging, 2021, 5, 155-156.	0.0	0
958	Successful cognitive aging definitions and associated demographic, biomarker profiles and lifestyles in the 80+ MCSA population. Alzheimer's and Dementia, 2021, 17, .	0.4	0
959	Posterior Cingulate Involvement Does Not Argue Against LATE. Journal of Nuclear Medicine, 2022, 63, 1282-1283.	2.8	0